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Background: Severe obesity is a chronic disease entailed by increased risk of obesity-
related comorbidities, impaired quality of life (QOL) and early death. Causes and 
consequences are multifactorial and reflect an interplay between biological, 
psychosocial and environmental factors. Bariatric surgery has evolved as a treatment 
option, providing weight loss and improvements in health. Vertical sleeve gastrectomy 
(VSG) is the latest and most frequently performed bariatric procedure worldwide, but 
data on long-term efficacy is scarcely reported. Little is known about factors that can 
explain the variability in long-term outcome after bariatric surgery. It is necessary to 
identify predictors of sustained weight loss and QOL improvements for a tailored 
patient-centric support.  
 
Objectives: The main objective of studies I-III was to report long-term outcomes in 
terms of weight, obesity-related comorbidities and QOL after VSG. Firstly, we report 
five-year complication and revision rates, weight loss and changes in comorbidities 
(primarily type 2 diabetes, hypertension and gastroesophageal reflux disease (GERD)). 
Secondly, previous studies found that self-efficacy may be a predictor of behavioral 
change and long-term health outcome. We therefor assessed the association between 
self-efficacy related to eating, weight loss and obesity-specific QOL five years after 
VSG. Thirdly, long-term reports on QOL after VSG are particularly limited. We 
assessed QOL broadly, covering obesity-specific and generic health-related QOL, as 
well as overall life satisfaction, and examined the association between weight loss and 
all levels of QOL five years after VSG.     
 
Methods: Demographic, clinical and patient-reported data from three separate patient 
cohorts was collected prospectively up to five years after VSG. In studies I and III, the 
data was extracted from the local obesity surgery registry in Førde Central Hospital, 
while the data in study II was collected at Voss Hospital. Eating self-efficacy was 
measured by the Weight Efficacy Lifestyle Questionnaire Short-Form. Health-related 
QOL and overall life satisfaction were measured by the Impact of Weight on Quality 
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of Life-Lite, the Obesity-Related Problem Scale, Short-Form-36 and Cantril’s ladder. 
All outcomes on QOL at five years were compared to population norms. 
 
Results: In studies I-III, 168, 114 and 127 VSG patients were included with five-year 
participation rates of 82, 74 and 64%, respectively. Mean weight loss was profound 
and significant in all cohorts from baseline to five years, but modest, significant weight 
regain was seen between one/two and five years after VSG. In study I, complication 
and revision rates were low, and most obesity-related comorbidities significantly 
improved from baseline to five years, with a notable exception of GERD. The 
prevalence of preoperative GERD increased from 12 to 35% at five years after surgery. 
Remission rates of type 2 diabetes and hypertension were 63 and 60% at five years, 
respectively. In study II, changes in eating self-efficacy from baseline to one year 
predicted weight loss at five years, as opposed to preoperative eating self-efficacy. 
Improvement in eating self-efficacy from baseline to five years was associated with 
greater weight loss and better obesity-specific QOL at five years after surgery. In study 
III, clinically and statistically significant improvements from baseline to five years 
occurred in all three levels of QOL, with significant yet modest deteriorations seen 
between one and five years after surgery. Greater weight loss five years after surgery 
was significantly associated with improvements in obesity-specific QOL and physical 
health-related QOL, but not with mental health-related QOL and overall life 
satisfaction. All mean scores on QOL at five years after VSG were below population 
norms. 
 
Conclusions: VSG is a safe and effective treatment of severe obesity. A majority of 
patients studied obtained enduring weight loss and improvements in health and QOL. 
Particular attention needs to be paid to symptoms of GERD after VSG. Still, over one 
third of patients experienced subsequent weight regain of 10 kg or more, and average 
QOL deteriorated between one or two and five years after VSG. Hence, an important 
minority of patients report less beneficial long-term outcomes after VSG, and some 
patients exhibit further deterioration in QOL compared to preoperative reports. The 
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observed associations between eating self-efficacy, long-term weight loss and QOL, 
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Daniel Lambert was reportedly the heaviest man in England back in 1770 [1]. By his 
death at 39 years old, his anthropometrics were a height of 180 cm, weight 335 kg, 
waist 284 cm and calf circumference 94 cm. Literary sources portray Mr. Lambert with 
words like “portly”, archaically defined as “stately” or “imposing”, thus representing a 
prosperous gentleman. Modern dictionaries, however, provide several pejoratively 
charged synonyms, such as “corpulent”, “stout” or “fleshy”. Although Lambert seems 
to have been a popular man, well liked and considered a human wonder by his 
contemporaries, sentiments have been expressed in modern times by the word “fatty” 
appearing spray-painted on his tombstone. This example of linguistic disparity might 
well be said to represent a time-driven transformation of attitudes towards obesity – 
from greatness to indulgence, from seldom and rare and thus valuable, to common and 
increasingly a manifestation of character flaw.  
In 2008, Voss Hospital’s department of surgery, my formative workplace for nearly 
two decades, was commissioned to perform surgery on individuals suffering from 
severe obesity. In this setting, working as a nurse, I first observed severe obesity as a 
medical condition, and my attitudes and judgements were probably biased: patients’ 
lack of self-control, proof of pure hedonism, ignorance and sloppiness. Fortunately, 
these preconceived attitudes were transformed as a result of day-to-day care of patients 
with obesity during my tenure as a ward- and outpatient nurse. Their experiences of 
prejudiced neglect, commonly performed by health professionals, have been 
ubiquitous. This tendency to interpret and judge other people simply by appearance or 
behavior is well known; we see what people look like, to a limited extent how they 
behave, and draw our premature conclusions. Though unconscious, these internalized 
verbal and non-verbal expressions of weight bias are offensive in form and ignorant in 
content. Treatment-seeking patients with severe obesity are all too often aware of their 
unhealthy life choices. In my experience, patients commonly express the following 
sentiment: “I know – the problem is in between my ears”. Such a belief reflects 
universal attitudes, and contributes to the already prevalent guilt of people with this 
disorder. If the brain, which governs and interacts with more of our body than the space 
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between the ears, does not respond adequately to simplistic application of the laws of 
physics, one might consider other strategies to hold up in front of individuals with 
obesity than the energy balance equation. 
 
A bigger picture 
The evidence of human obesity goes back over 20 000 years, based on the 
archaeological findings of Venus von Willendorf in Germany [1]. Meticulous details 
in sculptures unearthed that the artist made a true representation of a woman with 
extreme obesity. Thus some people suffering from severe obesity appear to have 
existed from prehistory, probably with a strong genetic or pathological component.  For 
decades, researchers developed increased understanding of the genetic component that 
together with environmental influence underpin weight-related behavior. The 
underlying genetic factors that are contributing to today’s growing proportion of people 
becoming obese, have likely existed in our species for a long time. We have not 
suddenly become more genetically prone to obesity. Scientists maintain that obesity 
was once adaptive as so-called thrifty genes enabled efficient storage of energy 
between famines. In modern prosperous societies, famines do not occur. What we 
experience is thus a mismatch between our evolved biology and our modern lifestyle 
which will, for many of us, result in sustained weight gain. So why do many people 
remain lean in modern prosperity? One suggestion is that the predisposing obesity 
genes are neutral and have been drifting over time, which leads some individuals to be 
obesity-prone, and others obesity-resistant.  
In most scientific explanations, obesity is an evolutionary maladaptive consequence. 
The simplistic notion that obesity is caused by lack of willpower, can thus safely be 
retired - and rest in peace.  
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1. Introduction 
Globally, there has been a fourfold increase in overweight and obesity over the last 
four decades, and the Norwegian population has followed this trend [2, 3]. The 
epidemic dimension has become a major public health concern. Besides being defined 
as a chronic, progressive disease in its own [4, 5], obesity is a risk factor for a range of 
diseases, increased mortality and reduced quality of life (QOL) [6-8]. Given the 
predicted increase in overweight and obesity [9], we can expect a concurrent increase 
in individuals with severe obesity, entailing individual suffering and socioeconomic 
load [10]. Prevention is better than cure, but effective treatment options for those 
already affected are needed.  
Different surgical procedures may result in long-lasting weight loss and improvements 
in health and QOL in a substantial proportion of patients with severe obesity [11-14]. 
When compared to non-surgical lifestyle interventions, bariatric surgery has shown 
better results [15]. The technical procedures have been changed continuously and 
refined to improve outcomes and reduce adverse effects. Accordingly, it is important 
to survey the safety and efficacy of new surgical methods. To this end, long-term results 
and adequate controlled trials are needed for a full evaluation. 
The conception of this thesis was a response to the Norwegian Research Centre for 
Health Services’ call for scientific updates on long-term efficacy of bariatric surgery 
[16]. Their systematic review in 2014 compared obesity surgery to non-surgical 
interventions, or no treatment. A general knowledge gap concerning adverse events 
and long-term results was identified [17].  
In three studies, we investigated five-year results on surgical complications, weight 
loss, obesity-related comorbidities and QOL after the most recent and now most 
commonly performed bariatric procedure: Vertical sleeve gastrectomy (VSG). 
Furthermore, possible predictors of weight loss and postoperative QOL after five years 
were examined.   
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1.1. Obesity  
1.1.1. Classification and measures 
Classifying levels of obesity in medicine and health care is mainly motivated by 
assessments of health risks (see section 1.1.3.) and treatment for the different risk 
categories. Currently, the most widely used classification in adults is based on the body 
mass index (BMI); body weight in kilograms (kg), divided by height in meters (m) 
squared (Table 1). The World Health Organization defines overweight and obesity as 
abnormal or excessive fat accumulation that may impair health [3]. The normal range 
is defined as BMI from 18.5 to < 25, associated with the least risk of health 
complications. This is not a statistical definition; in a population with increasing body 
weight, the average and thus normal range may well be above this interval. BMI values 
above 25, but below 30 kg/m2 characterize a pre-obese state. Obesity class I is defined 
as BMI ≥ 30 to < 35 kg/m2, class II as BMI ≥ 35 to < 40 kg/m2 and class III as BMI ≥ 
40 kg/m2. In this thesis classification of obesity is based on BMI. We use the term 
severe obesity, defined as BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with one or more 
obesity-related comorbidities [3, 6].  
 
Table 1  
Classification of adult underweight, overweight and obesity according to BMI [6] 
Classification   BMI kg/m2  Risk of comorbidities 
Underweight   < 18.5   Low (but risk of other clinical  
     problems increased)    
Normal range    18.5 to < 25  Average  
Overweight:    ≥ 25 
 Pre-obese   25 to < 30  Increased 
 Obese class I   30 to < 35  Moderate 
 Obese class II  35 to < 40  Severe 
 Obese class III  ≥ 40   Very severe 
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A classification based on BMI, a measure of relative body size, may belie the real 
extent and distribution of excess adiposity or body fatness, the metabolic phenotype of 
interest [18]. Other measures of adiposity have been introduced, such as increased 
waist circumference that provides information of abdominal fat or central adiposity. 
Together with high blood sugar, abnormal lipid levels or high blood pressure, an 
increased waist circumference is a hallmark of the metabolic syndrome, and has been 
proposed as a risk estimator for complications of obesity [6, 19, 20]. Other more refined 
laboratory measures of fat distribution, such as bioelectrical impedance, underwater 
weighing, dual-energy X-ray absorptiometry scanning, computed tomography and 
magnetic resonance imaging, may estimate the details of fat tissue content and 
distribution more accurately [21, 22]. However, these methods are technically 
demanding and their ability to assess risk associated with obesity is not yet validated 
[23]. In practice, BMI is still used due to its high correlation with more sophisticated 
methods, high predictive capacity for important outcomes such as mortality due to 
cardiovascular disease (CVD), along with its practicality [6, 10]. Nonetheless, 
biomarkers beyond anthropometric measurements may provide a more personalized 
and precise identification of individuals at risk of disease development [23]. 
 
1.1.2. Epidemiology – global and national trends 
The global epidemic of obesity has been named “a rising tide”, visualizing the 
uncontrolled and rapid growth in obesity [3, 24].  A 2016 update estimated above 1.9 
billion adults being overweight, of these 650 million are classified as having obesity 
[3]. All countries are affected, with differences in prevalence over time related to 
geographic, demographic and ethnic distribution [25-28]. Sociocultural, economic, 
political or physical inequalities between countries may to some extent account for 
these differences in prevalence of obesity [29].  
A threefold increase in the prevalence of obesity from 1975 to 2016 was observed both 
in the US and Norway [26]. For Norway, the proportion of individuals with obesity 
was estimated to be 7.7% in 1975 rising to 24% in 2016. Similarly, in the same period 
there was a six-fold increase in the prevalence of severe obesity from 1.2% (1.9% in 
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women and 0.4% in men) to 7.8% (8.6% in women and 6.9% in men). In 2016, the 
average BMI in the Norwegian population was estimated to 26.9 kg/m2, i.e. being 
overweight according to classifications based on health risk, is the statistical norm [26]. 
Socio-cultural and economic factors, such as family income, level of education, 
ethnicity, and geographic urbanity, are associated with the prevalence of obesity [27, 
30, 31]. It is difficult to conclude how these socio-economic factors relate causally to 
obesity as they may not only be risk factors for later development of obesity. Social 
inequalities may also be consequences of comorbidities, reduced QOL, or a result of 
how individuals with obesity are met by their environment (weight stigma). Hence, 
obesity may have a negative impact on labor market outcomes which, in turn, reinforce 
existing social inequalities in a self-sustaining manner [32, 33]. 
 
1.1.3. Etiology 
Energy homeostasis is an important characteristic of life. Obesity results from a 
positive energy balance in that energy consumed over time exceeds energy expended. 
This excess energy is stored as fat and consequently results in increased body weight. 
Hunger and satiety are complex responses to energy demands of the body and 
perceptions involving integration of stimuli between many neural sites, as well as 
peripheral organs and the brain [34, 35]. Physiology and behavior act in a coordinated, 
regulated manner [1]. The question to be answered, both to explain the epidemic rise 
in obesity on a population level and the difficulties for many individuals to maintain 
body weight within desired levels, is thus why some individuals fail to keep this 
balance. Multiple personal (genetic, physiological or psychological) and environmental 
factors associated with the risk of obesity have been described, but still there is a gap 
in knowledge on how these factors interact [36].   
 
Genes and the environment 
Genetic factors may be important determinants of obesity. The thrifty gene hypothesis 
suggests that the underlying genetic profile predisposes individuals to adverse or 
beneficial effects of environmental exposures, such as diet and exercise [36]. Findings 
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in ethnic groups, such as the Pima people and Pacific Islanders, as well as family and 
twin studies show a genetic predisposition for obesity in humans [37]. Advances in 
molecular biology have allowed the detailed genetic and epigenetic profiling of 
individuals, looking specifically at the genetic basis of body weight regulation [38]. 
Nevertheless, as of today, the ability to predict or explain weight development in an 
individual, or to explain population variability based on the genetic profile, is limited. 
In a 2010 study, common genetic variants associated with susceptibility to obesity 
account for less than 1.5% of the overall inter-individual variation in BMI [39]. 
Accordingly, individuals with the highest genetic risk were observed to have only 2.7 
kg/m2 higher BMI on average than those at low genetic risk. A recent Norwegian 
population study revealed that individuals with the lowest genetic risk also gained 
weight throughout the last decades, although to a lesser degree than the high-risk 
individuals [40]. Accordingly, there is evidence that even a low-risk genetic profile 
does not fully protect against obesity. 
 
In recent years, animal and human studies of gene-expression have shed light on weight 
regulation in mammals [38]. Maternal eating behavior and weight seem to have 
sustained effects on fetal life and later weight development, apparently by fetal 
programming via epigenetic mechanisms [41, 42]. In animal models, increased 
perinatal nutritional exposure exacerbates the sensitivity to an obesogenic food 
environment later in life [43]. Such findings have implications for the obesity epidemic 
of future generations.  
 
Homo sapiens evolved genetically in environments with lower and less predictable 
food availability than we are facing in most parts of the world today. We are genetically 
selected for survival in environments where starvation is a larger threat than obesity. A 
genetic constitution very similar to our ancestors, ready access to processed, highly 
palatable food along with historically low demands for physical activity may be 
regarded major contributors to the obesity epidemic. Thus, the interaction between 
ancient genes and a modern obesogenic environment can lead to weight gain, and in 
turn, sabotage efforts of obesity management [44]. Corrections of these environmental 
 24




“I'm a food addict. I've tried everything - Weight Watchers, The South Beach, raw food, 
Atkins, low-fat diets. Nothing works for me." I looked at him and said, "Have you tried 
suffering?" He laughed out loud, as if I was joking. I wasn't joking.”  
(Dr. Frederick Woolverton) 
 
Eating behavior is a major contributor to overweight and obesity. Despite a genetic and 
biological basis, eating behavior is, to some extent, modifiable. Though feeling of 
hunger may be a powerful biological motivation to eat, people can consciously or 
unconsciously choose whether, when and what to eat. A growing body of evidence 
suggests a close relationship between obesity and psychological components 
comprising mood disturbances, altered reward perception, motivation or addictive 
behavior [37]. Identifying personal traits or skills that impact our eating behavior, may 
therefore be important to understand the development of obesity and the success of any 
therapeutic intervention [45].  
 
To illustrate, two recent studies shed light on the personal efforts that may be needed 
to cope with increased appetite and reduced energy expenditure associated with 
conservative weight loss interventions [46, 47]. In a yearlong placebo-controlled 
weight loss trial of cangliflozine (an anti-diabetic drug that inhibits renal re-uptake of 
glucose) in patients with obesity and type 2 diabetes, average body weight decreased 
significantly more than in the placebo group [46]. Modelling the physiological 
response to weight loss, the authors found that appetite increased and energy 
expenditure was reduced due to weight loss, the latter phenomenon called metabolic 
adaptation. The few participants who successfully maintained long-term weight loss 
did so by “heroic efforts” to resist increased appetite in face of reduced energy 
expenditure. Similar findings are reported for individuals with obesity six years after 
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participation in the US “Biggest Loser” competition [47]. Overall, the participants 
experienced a substantial weight regain, but the metabolic adaptation persisted. 
Paradoxically, those with greater long-term weight loss also had greater ongoing 
metabolic slowing. Thus, the authors suggested that overriding the persistent metabolic 
adaptation of weight loss requires a “vigilant combat”.  
 
Different patterns of pathological eating have been implicated in the development of 
obesity [48, 49]. Among different forms, binge eating disorder and loss-of-control 
eating are commonly associated with increased risk of overweight and obesity. Both 
are further related to high prevalence of psychiatric and physical comorbidities. 
Treatment-seeking individuals with obesity seem to report pathological eating more 
frequently than those who do not seek treatment, and binge eating disorder is observed 
in up to 49% of patients undergoing bariatric surgery [50, 51].  
 
1.1.4. Consequences  
Society’s perception of obesity, as described above, has varied over time and being 
overweight is now normal in our population. From a medical perspective, overweight 
and obesity attract attention mainly because of their association with a number of other 
diseases, reduced QOL and shortened life expectancy. For society, increased obesity 
results in increased health expenditure. Correction of obesity by treatment may lower 
the burden of such comorbidities, improve QOL and prolong life. Neither societal 
attitudes nor population average weight should distract from this important medical 
perspective toward obesity.  
 
Morbidity   
Obesity is significantly associated with the risk of a series of comorbidities and 
conditions, such as hypertension, high blood levels of cholesterol and/or triglycerides 
(commonly called dyslipidemia), type 2 diabetes, CVD, osteoarthritis, sleep apnea and 
breathing problems, cancer and mental illness [52-54]. In a recent Norwegian study, 
the most prevalent comorbidities in men with obesity were non-alcoholic fatty liver 
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disease, dyslipidemia and hypertension [55]. In women, dyslipidemia, fatty liver 
disease and joint pain were most common. 
For the scope of this thesis, the most relevant obesity-related comorbidities are type 2 
diabetes, hypertension and gastroesophageal reflux disease (GERD). An estimated 
85% of all patients with type 2 diabetes, defined as glycated hemoglobin (HbA1c) ≥ 
6.5% and fasting blood glucose (FBG) ≥ 7 mmol/L, either have overweight or obesity. 
Approximately 25% of people with obesity have type 2 diabetes [56, 57]. Similarly, 
obesity is believed to account for an estimated 77% of hypertension, defined as blood 
pressure ≥ 140/90 mmHg, in men and 65% in women, and the prevalence of 
hypertension in people with severe obesity is three times the prevalence in people with 
a normal body weight [58]. The risk of hypertension increases continuously with BMI, 
with a suggested relative risk of about 1.5 for a five unit increment in BMI [59, 60]. 
GERD, characterized by reflux of stomach content causing heart-burn and acid 
regurgitation, is commonly diagnosed in patients with obesity, presumable due to high 
intra-abdominal pressure [61, 62]. Available estimates suggest a weight gain greater 
than 3.5 kg/m2 is associated with approximately two- to three-fold increased risk of 
developing reflux symptoms [63]. Most studies on psychiatric disease in obesity have 
focused on depression, but among others, anxiety disorders, eating disorders and 
alcohol abuse have been evaluated [54, 64]. The association between depression and 
obesity appears to be bidirectional. Psychiatric symptoms and mental disease are 
important comorbidities to evaluate before and after weight loss interventions, and 
have also been explored as predictors of weight loss (section 1.4.) 
 
Quality of life 
By considering QOL in medicine, the patient’s own perception of well-being is set 
alongside biomedical readings as an important perspective on disease. The World 
Health Organization has defined health as “the state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity” [65]. QOL is a 
broader term than health with no universally accepted definition, but commonly 
includes well-being, happiness, life satisfaction, attainments of goals, meaning in life 
and functioning [66]. Improvement in health is the main goal of medical treatment, and 
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consequently QOL represents an important outcome measure. For this purpose a more 
specific definition of health-related QOL has been provided: “A term referring to the 
health aspects of QOL, generally considered to reflect the impact of disease and 
treatment on disability and daily functioning; it has also been considered to reflect the 
impact of perceived health on an individual’s ability to live a fulfilling life” [67]. 
QOL is an example of a patient-reported outcome (PRO) relevant in bariatric surgery 
research and clinical practice. The intention of utilizing PRO is to capture patients’ 
perspectives on their own health. Thus, “a patient-reported outcome (PRO) is directly 
reported by the patient without interpretation of the patient’s response by a clinician 
or anyone else and pertains to the patient’s health, QOL, or functional status 
associated with health care or treatment” [68, 69]  
Obesity has been shown to negatively impact physical, psychological and social 
functioning, comprised by health-related QOL [70-72]. An inverse relationship 
between obesity and overall life satisfaction has also been found in several studies [73, 
74]. Furthermore, individuals with obesity who seek treatment report poorer health-
related QOL than those who do not [75, 76], and the poorest health-related QOL has 
been found in individuals with severe obesity who choose to undergo bariatric surgery 
[71, 75, 77]. In 1993, QOL assessments were included in standards for evaluating 
obesity interventions [78]. 
Obesity has been found to negatively impact different aspects of life. In general, these 
effects have been described on three levels of QOL; 1) overall QOL, covering 
satisfaction with life as a whole 2) generic physical and mental health and 3) obesity-
specific QOL. The latter two represent examples of health-related QOL [79, 80].   
 
Mortality 
Obesity is an important risk factor for reduced life expectancy in Western populations. 
Recently the risk was estimated to loss of three to four disease-free years in individuals 
with obesity class I, and seven to eight disease-free years in case of severe obesity [81]. 
Above a BMI of 25 kg/m2, each additional 5 kg/m2 is associated with 30% higher 
overall mortality, 40% higher vascular mortality and 60-120% higher diabetic, renal 
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and hepatic mortality. Median survival at BMI 40-45 kg/m2 was estimated as reduced 
by 8-10 years, comparable with the effects of smoking [82]. Similar findings pertain to 
the Norwegian population [83, 84]. Furthermore, it has been calculated that the number 
of disability-adjusted life years lost due to overweight accounted for 6.5% of all life 
years lost in the Norwegian population in 2016 [85]. High BMI is one of the most 
important risk factors for loss of health and longevity in Norway. 
 
Weight stigma  
Research has consistently documented discrimination against individuals with obesity 
[86-90]. Weight stigma can be defined as the social rejection and devaluation that affect 
people who do not adhere to prevailing social norms of body weight and shape [86]. 
Stigmatization itself has negative implications for weight-related health [90, 91]. In 
addition to psychosocial and economic consequences, discrimination tends to reinforce 
adverse health behaviors that in turn exacerbate obesity and poor health. As examples, 
Norwegian studies of weight stigma have emphasized patients’ experiences of 
prejudice from health professionals as barriers for adequate medical treatment and 
desired weight loss [88, 92]. Overall, stigmatization poses a threat to preventive and 
therapeutic efforts [86, 91].  
 
Social costs  
The economic burden on society also motivates prevention and treatment of obesity. It 
has been estimated that health problems related to overweight and obesity account for 
2-7% of total health care costs in industrialized countries and 3% of total global health 
costs [93]. For Norway, 70 billion Norwegian kroner are estimated to be spent directly 




1.2. Management of obesity 
Both treatment and prevention, be it primary or secondary, are needed to address the 
increase in obesity, and to improve the health, functioning and QOL of individuals with 
obesity [94]. In Norway, a diagnosis of severe obesity grants access to treatment within 
the public health services [95]. Currently, three treatment modalities are available: 
Lifestyle intervention, pharmacotherapy and bariatric surgery.  
 
1.2.1. Conservative interventions 
Different lifestyle interventions for obesity, focusing on diet, physical exercise and/or 
behavioral therapy, reveal modest outcome in terms of weight loss [96-98]. After 
intensive lifestyle interventions, average weight loss of approximately 10% at one year 
is observed, with 5% of weight loss maintained over longer periods. Nonetheless, 
patients may experience clinically meaningful health benefits, such as improved 
glycemic control, reduced blood pressure and lower cholesterol levels, even when body 
weight is reduced by only 10% or less [99, 100]. Low costs and minimal risk of 
complications suggest that such lifestyle interventions should be the first options 
considered for patients with obesity [101, 102]. However, even when losing weight 
during or shortly after an intervention, the majority of patients seem to regain most, all 
or more weight than they initially lost [47, 103, 104].   
The improved understanding of biological mechanisms regulating appetite, food 
uptake and metabolism, has allowed for pharmacological interventions to treat obesity. 
So called anti-obesity drugs have been introduced primarily as adjuncts to other 
conservative forms of therapy [105, 106]. Three types of weight-reducing drugs are 
approved and currently available in Norway: Xenical® (orlistat), Mysimba® (A 
combination of naltrexone and bupropion), and recently Saxenda® (liraglutide) [107]. 
In short-term clinical trials, an increased average weight loss of 4-8% of body weight 
compared to placebo while on drug therapy is typically reported [105, 106]. A concern 
with pharmacological treatment is that weight tends to rise when treatment is 
discontinued [108, 109]. Long-term use of anti-obesity medication may be necessary 
for sustained weight control. Disappointing results in terms of weight loss, adverse 
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effects and substantial costs, may explain why these drugs are not used extensively 
[101, 110]. Of interst, liraglutide has been studied as short-term treatment in patients 
with poor weight loss or weight regain after bariatric surgery [111].   
 
1.2.2. Bariatric surgery  
Bariatric surgery, also termed metabolic surgery, includes a number of procedures that 
work primarily by restricting food intake and/or absorption of nutrients. It has been 
proposed that bariatric surgery may also alter gut hormones and thereby contribute to 
weight loss and metabolic benefits [112].   
   
 Weight-reducing and metabolic effects of small bowel bypass surgery in animals and 
humans were first published in the 1950s and 60s, respectively [113, 114]. During the 
ensuing decades, refinements and new surgical techniques were introduced, motivated 
to a large extent by the recognition of long-term complications associated with earlier 
procedures [115-117]. The same concern about adverse effects led to an overall 
skepticism to bariatric surgery in the global medical community during the 1980’s, also 
in Norway [116]. Still, evidence suggested that the procedures in use were safe and 
effective for patients with severe obesity [118]. Hence, to help legitimize bariatric 
surgery as a treatment option, previously missing standards for practice were 
established in 1991 [118, 119]. Since then, the use of bariatric surgery markedly and 
continuously increased.  
 
The Swedish Obese Subjects (SOS) Study started in 1987 as a non-randomized, 
matched intervention trial [11, 120]. This is so far the longest running trial of bariatric 
surgery worldwide. With the limitations of a non-randomized comparison, it has shown 
what can be achieved by surgery, including decreased overall mortality, remission of 
type 2 diabetes, fewer CVD events, decreased risk of certain cancers and lowered 
medication costs compared to conservative treatment [11, 119]. The most frequently 
performed surgical procedures in SOS are, however, rarely performed today.  
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At present, an estimated 3000 bariatric operations are performed in Norway annually, 
and about 2/3 of these are publicly funded [121]. No data exist concerning Norwegian 
patients who choose to have bariatric surgery performed abroad [122].  
Bariatric procedures in current use  
Today, a variety of improved bariatric procedures are in use. Knowledge of their 
relative efficacy and risks, and whether different procedures may be appropriate for 
different categories of patients is needed [123, 124].  
 
According to global estimates, more than 600 000 primary bariatric operations were 
performed in 2016 [125]. This number encompasses 54% VSG, 30% Roux-en-Y 
Gastric Bypass (RYGBP), 5% one-anastomosis gastric bypass, 3% adjustable gastric 
banding and 0.5% biliopancreatic diversion with duodenal switch (BPDDS) [125]. 
With incomplete coverage, this trend is mirrored by the national obesity surgery 
registry in Norway (SOReg-Norway) where VSG accounted for 58% and RYGBP for 
42% of the primary operations performed in 2017 [121, 126].  
 
The procedures in scope for this thesis are presented below, with focus on VSG, the 
intervention studied, and RYGBP and BPDDS (in reverse, but historical order) for 
comparison and discussion purposes. Despite some use in recent years, other 
procedures are not discussed. 
 
Biliopancreatic diversion with duodenal switch 
The biliopancreatic diversion procedure was first developed by Nicola Scopinaro, and 
included a distal gastrectomy with a long limb and a short common channel [127]. The 
modification with a duodenal switch was introduced later to reduce the incidence of 
anemia and protein malnutrition. BPDDS involves a substitution of the distal 
gastrectomy by a VSG to preserve vagal innervation and pyloric function [128]. 
Although BPDDS results in greater weight loss and higher remission rates of type 2 
diabetes, it is associated with higher rates of complications and risk of mortality than 
other surgical procedures in current use, and is rarely performed today [125, 129]. 
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Roux-en-Y gastric bypass 
The first gastric bypass was performed by Edward E. Mason after recognizing that 
patients with sub-total gastrectomy for cancer experienced considerable weight loss 
[130]. To prevent bile reflux, a reconstruction with a “Roux-en-Y” loop was developed 
[131]. This procedure has until recently been considered the gold standard among 
bariatric operations. RYGBP is suggested to work by restricting food intake, rerouting 
the food stream and changing gut hormones [129]. 
 
Vertical sleeve gastrectomy 
VSG was initially proposed as a first, restrictive step of the full BPDDS procedure for 
patients with a very high BMI (Figure 1). Later, the efficacy of VSG as a stand-alone 
bariatric procedure was recognized by Michel Gagner and colleagues [132]. In brief, 
the procedure involves removal of 80-90% of the stomach, in particular the fundus, 
leaving a narrow «sleeve» between the esophagus and the duodenum. Otherwise, the 
gastrointestinal tract is undisrupted. Weight loss and metabolic benefits after VSG are 
believed to result from restricted energy intake, accelerated gastric emptying and 
altered gut hormones [129].  
 
Figure 1. Vertical Sleeve Gastrectomy (Reprinted with permission, Cleveland Clinic Center for 
Medical Art & Photography © 2019 All Rights Reserved) 
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VSG has recently become the most common bariatric procedure worldwide and in 
Norway, slightly above RYGBP [125, 133]. As of 2016, only two small randomized 
trials from China were available with five years follow-up, but none of them allow a 
full comparison of the two procedures [134, 135]. Still, there are some conceptions 
why VSG may be preferable to RYGBP. VSG does not require anastomoses, and may 
represent a versatile first step of most other procedures [136]. In addition, patients’ 
preferences may contribute to the choice. However, until a few years ago, few long-
term studies on VSG had been published and no randomized comparisons to RYGBP 
with adequate numbers of patients and follow-up had been reported.  
 
Recommendations for pre- and postoperative care  
Pre- and postoperative follow-up, recommended to be carried out by a 
multidisciplinary team, are mandatory in bariatric surgery [137-139]. Minimal 
requirements for follow-up are: 1) Check-up after one month, minimal follow-up every 
three months for the first year, every six months for the second year and annually 
thereafter. 2) Prescription of vitamin and micronutrient supplements and annual 
laboratory tests to evaluate metabolic and nutritional status. 3) Regular contact with 
and lifelong follow-up at an obesity management center [137, 139]. 
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1.3. Outcomes after vertical sleeve gastrectomy  
As VSG is a relatively new bariatric procedure, long-term data from prospective studies 
has been lacking [140-143]. By 2015, data beyond two years after VSG was not 
available for the Nordic countries or Norway [144, 145]. This section provides a basic 
summary of outcomes close to or above five years after VSG, as published by the time 
the research work of this thesis started, focusing on endpoints addressed in studies I-
III. The results of studies I-III will be discussed further in section 4.3., with reference 
to research on long-term outcome evolving after 2016.  
 
1.3.1. Weight loss 
Reporting weight and weight loss data in bariatric surgery research is recommended to 
include initial BMI, change in BMI, percent of total weight loss (%TWL), percent 
excess BMI loss (%EBMIL) and/or percent excess weight loss (%EWL) [62]. 
Nevertheless, reported weight loss measures vary among studies, commonly using 
either %EWL or %EBMIL [140, 146, 147]. By using ideal weight corresponding to 25 
kg/m2 in the %EWL formula, % EBMIL provides identical information. Although not 
universally accepted, a threshold of < or ≥ 50% EWL is most commonly reported as 
weight loss “failure” or “success” after bariatric surgery [147]. 
In a 2014 systematic review, Puzziferri and colleagues assessed 29 studies in which 22 
reported weight loss as a primary outcome two to five years after bariatric surgery 
[148]. Neither of the two retrospective cohort studies of VSG included reported five-
year weight loss data. A concurrent literature review focusing on VSG only, reported 
on 377 patients from 12 studies, with a follow-up of five years or more, and revealed 
an overall mean EWL of 59.3% [149].  Based on a review of 20, mainly cohort studies 
with more than five years of follow-up, Juodeikis et al. identified 17 studies with weight 
loss data from 1501 patients [140]. Only five studies included more than 100 patients, 
and the range of mean %EWL across studies was 40 - 86%. The calculated mean for 
all studies combined was 58.4% five years after VSG. As for other surgical procedures, 
after an initial steep weight loss a varying proportion of patients seemed to gain weight 
also after VSG [146, 150, 151].  
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1.3.2. Obesity-related comorbidities and mortality 
Common comorbid conditions related to obesity are discussed in section 1.1.4. Data 
on changes in type 2 diabetes, hypertension and GERD after VSG, as they were 
available in 2016, are presented below. 
 
Type 2 diabetes 
There is ample evidence that bariatric procedures may lead to improvement of type 2 
diabetes [62, 152]. The definition of remission of type 2 diabetes varies between studies 
and hampers comparative analysis. According to current standards for outcome 
reporting, a complete remission is defined as HbA1c < 6% and FBS < 5.6 mmol/L, 
partial as HbA1c ≤ 6.4% and FBS ≤ 7.0 mmol/L [62], both in the absence of 
medication.  
 
In their 2017 review, Juodeikis and colleagues identified 11 out of 20 studies that report 
on type 2 diabetes five years after VSG. They estimated remission or improvement 
rates, as referred to normal clinical parameters without medication or reduction in 
medical therapy, to a mean of 77.8% across all studies (range 61.5 to 100%) [140]. 
Only nine out of 11 reviewed studies reported remission criteria, and four used criteria 
as recommended [62]. Another partially overlapping review, focusing especially on the 




After bariatric surgery, improvement in hypertension is commonly defined as a 
decrease in use of antihypertensive medication, a reduction in blood pressure or both. 
According to standard criteria, complete remission is defined as blood pressure < 
120/80 mmHg, and partial remission <140/90 mmHg, both in the absence of 
medication [62]. Depending on the definition, early reports reveal varying rates of 
improvement five years and more after VSG [148, 154]. In their systematic review, 
Juodeikis et al., reported a mean improvement or resolution rate of 68% at five years 
after VSG, although with highly variable rates (range 28.6 to 95%) among nine relevant 
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studies [140]. Heterogeneous definitions of improvement or resolution may account 
for some of the variability between studies.  
 
Gastroesophageal reflux disease  
Symptoms related to GERD are reported as improved after different bariatric 
procedures [155]. Monitoring of GERD is recommended to include symptom reports 
from patients, preferably by validated questionnaires, use of antacid medication, or 
both. Complete resolution can be subjectively assessed by absence of symptoms and 
medication use, and objectively by physiological tests and/or endoscopy [62]. It has 
been suggested that GERD may worsen after VSG when present preoperatively, or that 
VSG may be followed by the development of de novo GERD [156, 157]. The rates of 
improvement, resolution or deterioration of GERD and the incidence of de novo GERD 
after VSG vary in early studies. A 2011 review of 15 early studies acknowledges the 
diverging results and difficulties in providing numeric data regarding the effect of VSG 
on GERD [158]. In the review by Juodeikis et al. two studies reported improvement of 
GERD symptoms, while eight studies reported new-onset GERD in 0-23% of patients 
at five years after VSG [140].  
 
Mortality 
The analysis of mortality after bariatric surgery, be it all-cause or due to specific 
complications of obesity, is mostly based on cohort or case-control studies. While 
smaller studies may have lacked statistical power to detect relevant differences in 
survival, larger studies with adequate follow-up point to benefits in terms of overall 
survival [159, 160]. Significant improvements in cause-specific survival from 
comorbidities, such as diabetes or cardiovascular disease are also detected [159]. There 
is no clear indication whether specific procedures, let alone VSG lead to better survival 






1.3.3. Complications and reoperations 
Benefits of bariatric surgery must be balanced against the risk of surgical 
complications. Postoperative complications after bariatric surgery may be classified as 
major or minor, occurring either early (≤ 30 days postoperatively) or late (> 30 days 
postoperatively) [62]. Major early complications may involve prolonged 
hospitalization beyond seven days, administration of an anticoagulant, reintervention 
or reoperation.  
 
Overall, the mortality rate within 30 days after bariatric surgery has been estimated 
between 0.07 and 0.35% [161, 162]. In early studies the most common major 
complications reported after VSG were bleeding, staple line leak, stricture and venous 
thrombosis [163]. While postoperative bleeding has been reported in up to15% of 
patients, staple line leak occurred more rarely – varying between 0 and 5.5% [163, 
164]. Stricture and thrombosis after VSG was seen in up to four and one percent of 
patients, respectively, but reoperation is rarely required [163]. Based on non-
randomized comparisons to RYGBP, VSG was estimated to have a somewhat lower 
rate of early complications [165, 166]. The most frequent reasons for reoperation 
described after VSG were GERD or insufficient weight loss [156, 167-169]. To the 
best of our knowledge, only limited Norwegian data on complications and reoperations 
after VSG was available as of 2016 [145].  
 
1.3.4. Quality of life 
As outlined in section 1.1.4., impairments in QOL are reported by patients with obesity. 
There are significant improvements in QOL after bariatric surgery demonstrated also 
in previous research from our group [14, 170-172]. In general, trajectories of QOL 
seem to coincide with postoperative changes in weight [172].  
At the time of commencement of this thesis, limited data on QOL five years after VSG 
was available. As reviewed by Juodeikis et al, only one of 20 studies (including 32 
patients) assessed pre- and postoperative QOL and reported a significant improvement 
at five years after surgery [135, 140].  Four other studies were cross-sectional and 
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reported QOL at different points in time after VSG. One of these compared QOL of 
three smaller cohorts at one, three and five years postoperatively, showing a decline in 
some aspects of QOL at five years compared to one year [173]. A range of different 
questionnaires was used across studies, making comparison of results difficult. Thus 
comprehensive and prospective studies on QOL, using well established tools, were 
warranted. 
Methodological and conceptual considerations related to the evaluation of QOL are 
addressed further in section 4.2.4.   
 
1.4. Predictors of weight loss and quality of life in bariatric surgery 
Identifying patients who are most likely to benefit from surgery is important to 
optimize resource allocation, avoid exposing patients unlikely to benefit, manage 
patients’ expectations and tailor follow-up. Several studies have evaluated factors that 
may predict weight loss and other outcomes following bariatric surgery [124, 174-177]. 
Conceptually, characteristics assessed before or after treatment, and time dependent 
changes of such factors after surgery could be used to predict outcome. Weight 
reduction has been evaluated as the outcome of interest in most studies, but it may be 
argued that resolution of comorbidities, functional or psychological improvement, 
QOL and increased life expectancy, are additional or more appropriate goals to aim for 
in this regard.   
 
Predictors of weight loss  
No commonly accepted predictors for weight loss after bariatric surgery seem to exist 
[124, 178-180]. Preoperative BMI, type 2 diabetes, education, marital status, sex, age, 
ethnicity and socioeconomic factors have been evaluated as predictors of weight loss 
after different procedures, but results vary. With considerable heterogeneity between 
studies, recommended preoperative weight loss may be positively associated with 
postoperative weight loss, whereas higher preoperative BMI, superobesity (defined as 
BMI ≥ 50 kg/m2) and certain psychosocial factors may be negatively associated with 
weight loss after surgery. Among such psychosocial factors, eating disorders, mostly 
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binge-eating disorder, other maladaptive eating behaviors, such as snacking, symptoms 
of depression or anxiety and alcohol abuse have been studied, but no uniform results 
are seen [124, 175, 178, 181]. Norwegian guidelines recommend excluding patients 
with active psychosis or drug/alcohol abuse from surgery, which is enforced in all 
studies in the present thesis [95].   
 
Predictors of QOL 
Other studies have addressed predictors of QOL following bariatric surgery [177]. In 
one study, higher preoperative BMI and self-reported symptoms of depression were 
suggested as predictors for a lower level of health-related QOL determined 12 months 
after RYGBP [182]. Moreover, the association between postoperative improvements 
in depression and health-related QOL were found to be stronger than the association 
between weight loss and health-related QOL. Actual weight loss was mainly associated 
with the physical aspects of health-related QOL at 12 months. Others have also 
suggested that the predictors of physical health-related QOL and weight loss are 
similar, while the association between postoperative weight loss and mental health-
related QOL is not convincingly demonstrated [176]. Further studies also demonstrate 
the predictive capacity of preoperative age, BMI and depression severity [183, 184], 
and psychiatric disorders that persists postoperatively on health-related QOL both 
short- [177, 183, 185] and long-term after bariatric surgery [186]. It seems unclear 
whether pre- or postoperative eating behavior, e.g. maladaptive eating or binge eating, 
may predict health-related QOL [176, 177, 187]. Studies on early post-operative 
changes in psychosocial factors with potential relevance to long-term outcome, e.g. 
weight loss, QOL or others, are limited [188].  
 
1.4.1. Eating self-efficacy 
Eating behavior is introduced briefly in section 1.1.3. It has been suggested that 
bariatric surgery may affect key factors involved in regulation of eating behavior and 
hedonic taste perception [189]. These include food-craving, the influence of emotions 
and external food cues and the palatability of sucrose. Both restrictive effects of surgery 
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and changes in gut hormones may be mediators of these effects. Still, some patients 
struggle to change old eating habits even after bariatric surgery [190]. Physiological 
adaptation may be part of the problem [191, 192], but cognitive control of eating 
behavior seems crucial for weight management also after surgery [193].  
Self-efficacy is a key concept in social cognitive theory and refers to perceived 
capabilities of performing behaviors at designated levels [194, 195]. It may influence 
the choice of activities, effort, persistence and achievement. Information on ones self-
efficacy for a specific activity may be acquired from previous performance, vicarious 
experiences, forms of persuasion and physiological symptoms. Perceptions of progress 
and success, specifically mastery experiences, may reinforce self-efficacy, and thus 
promote the capacity to manage obstacles [195]. As such, individuals with high 
perceived self-efficacy seem to attempt more, accomplish more and persist longer at a 
specific task than those with low perceived self-efficacy. Levels of self-efficacy appear 
positively correlated with health-related self-management, for instance in adjustment 
to CVD and smoking cessation [196, 197]. Self-efficacy may therefore be a useful 
measure of patients’ self-management following weight loss interventions [198-200].  
While general self-efficacy may be defined as a universal measure of an individual’s 
ability to manage several different tasks and settings [201], Bandura argued that self-
efficacy is context-dependent [194]. Thus, self-efficacy could be considered a 
modifiable, situation-specific attitude that seems to be a stronger predictor of behavior 
than more stable personality traits [202]. Eating self-efficacy refers to the confidence 
to control eating in specific challenging situations [203]. A validated questionnaire of 
eating self-efficacy, the Weight Efficacy Lifestyle Questionnaire short-form (WEL-
SF) has been applied for research purposes [198, 203].  
Studies on the association between self-efficacy, whether general or related to eating 
or physical activity, and weight, have mainly focused on conservative weight loss 
interventions. The existing research does not fully support the conclusion that self-
efficacy is a valuable concept for predicting or improving health behavior and outcome 
in patients with obesity [204, 205]. However, important lessons can be learned from a 
number of these studies. It appears important to distinguish between studies of self-
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efficacy prior to an intervention and its ability to predict future weight loss, and self-
efficacy after treatment changing concurrently with weight loss. At the outset of this 
thesis work, no studies were available on the value of self-efficacy assessments prior 
to bariatric surgery. In a cross-sectional study, Batsis et al. compared eating self-
efficacy four years after either RYGBP or non-surgical treatment. They found that 
greater weight loss was associated with higher eating self-efficacy, and that the values 
were higher in the surgical group than in the conservatively treated patients [206]. In a 
cross-sectional study on Norwegian patients one year after VSG, we observed a similar 
correlation between weight loss and eating self-efficacy assessed postoperatively 
[198]. Prospective studies are, however, needed to investigate pre-surgical levels and 
changes in eating self-efficacy after surgery, and to explore their possible association 
with weight loss over time.  
Interestingly, there seems to be an association between QOL and both general self-
efficacy and health literacy [207-209]. Prospective assessments of the association 
between self-efficacy and long-term health-related QOL after bariatric surgery seem to 
be lacking.  
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1.5. Aims  
To summarize, patients seeking surgical treatment for severe obesity often suffer from 
obesity-related comorbidities and report poor QOL. VSG has recently become the most 
frequently performed bariatric surgical procedure worldwide and in Norway, but 
knowledge on long-term outcomes is still limited. Particularly, predictors of weight 
loss and QOL are scarcely examined after VSG. In this context, the aims of this 
doctoral research were: 
1.  To report five-year outcome after VSG, specifically complication and revision 
rates, weight loss measures and changes in obesity-related comorbidities (Paper 
I) 
2. To investigate the predictive value of eating self-efficacy on long-term weight 
loss and obesity-specific QOL after VSG (Paper II) 
3. To investigate 1) long-term trajectories in QOL at different levels (obesity-
specific and generic health-related QOL, and overall QOL) following VSG, 
compared to general population norms and 2) the predictive value of weight loss 






2. Materials and methods 
2.1. Settings and study design  
We studied three separate patient cohorts. For studies I and III, data was derived from 
the bariatric surgery registry at Førde Central Hospital. After a longer halt in bariatric 
surgery from about 1980, Førde Central Hospital was the first hospital in Norway to 
resume bariatric surgery for severe obesity in 2001. By establishing a local registry, 
research and quality control were emphasized from the outset. Since 2007, VSG has 
been the preferred procedure, with approximately 40 patients operated on annually. For 
study II, data was collected at Voss Hospital where bariatric surgery has been 
performed since 2008. Approximately 200 patients undergo bariatric surgery annually 
since 2012, with VSG being used in 90% of cases. From a national perspective, both 
hospitals have pioneered VSG as a bariatric surgical procedure.  
At Førde Central Hospital, all patients accepted for surgery are invited to contribute to 
the registry. Following informed consent, data from hospital charts and registry-
specific forms, including PROs, are entered prospectively. Studies I and III are covered 
by ethical approval of the registry (REK no: 2009/2174).  
Study II is a prospective study recruiting patients accepted for surgery at Voss Hospital 
(REK no: 2012/1481). Following informed consent, study-specific data from PROMs 
were collected and aligned with clinical data from hospital charts. The follow-up period 
of the study was later extended from two to five years (REK no: 2017/948).  
All three studies in this thesis have a prospective design based on five-year 
observational follow-up. 
 
2.2.  Participants 
Adult (18 to 70 years) patients with severe obesity (BMI ≥ 40 kg/m2, or ≥ 35 with 
obesity-related comorbidities) accepted for VSG based on standard criteria, i.e. absence 
of alcohol or drug abuse and active psychosis, as assessed by the multidisciplinary team 
and the treating surgeons, were invited to participate in the studies. In study I and III, 
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patients operated from December 2005 to November 2010, and from January 2010 to 
December 2013, respectively, were included. In study II, included patients were 
operated on from December 2012 to May 2013.  
 
2.2.1. Preoperative information and evaluation 
Before surgery, patients were invited to a multidisciplinary meeting with information 
about obesity, bariatric surgery and its risks, required changes in habits of eating and 
physical activity and likely life changes after surgery. This was followed by an 
individual and structured out-patient consultation (Appendix I) two to three months 
before the operation, with the surgeon and other health-personnel. Blood samples were 
taken after over-night fasting and routine clinical evaluation and relevant study 
questionnaires were completed (Appendix II). Preoperative advice centered on 
smoking cessation, increased physical activity, weight reduction and a diet restricted 
to 1000 kilocalories/day.  
 
2.3. The vertical sleeve gastrectomy 
VSG was performed according to identical technical standards in both institutions, as 
described [145]. In brief, the stomach was vertically resected along a 32 French (≈ 11 
mm) tube from 1-2 cm proximal to the pylorus ending at the cardia. Prophylactic staple 
line reinforcement and gastropexia (suturing the rest-stomach to the omentum) was not 
part of the standard procedure. Preoperative upper gastrointestinal endoscopy was only 
performed in selected cases, and perioperative hiatal repair was not performed.  
 
2.3.1. Postoperative evaluation 
After surgery, patients were followed with out-patient visits at three, 12, 24 and 60 
months. Consultations included blood samples after over-night fasting, weighing, 
blood pressure measurement and relevant study questionnaires. The operating surgeon 
participated regularly at the three-month visit, while later visits were done mainly by a 
nurse and nutritionist. All study visits followed a standardized checklist (Appendix I) 
and covered complications, physical and mental health, medication, physical activity, 
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nutritional intake, the need for supplementation and study questionnaires. Individual 
health challenges were addressed and, if needed, referral to other specialists was 
initiated. 
 
2.4. Variables and measures 
2.4.1. Demographic, anthropometric and clinical variables 
Demographic, anthropometric and clinical data was registered from hospital charts and 
standardized checklists (Appendix I). Data on patients’ age, sex, marital/cohabitation-
status, medically treated anxiety and depression, BMI and QOL are included in all three 
studies. Study I contained additional data on employment, medically treated 
comorbidities, early major complications and re-operations. Study II contained 
additional data on education level and eating self-efficacy. Body weight was measured 
in light clothing without shoes to the nearest 0.1 kg. Height was measured in a standing 
position without shoes to the nearest centimeter. BMI was calculated as weight divided 
by height squared (kg/m2). 
The American Society for Metabolic and Bariatric Surgery (ASMBS) standards guided 
the outcome definitions and assessments [62]. 
 
Weight loss 
Weight loss was presented as change in BMI (ΔBMI = initial BMI − postoperative 
BMI) or percentage total weight loss (TWL = (initial weight – postoperative 
weight/initial weight) x 100). In addition, loss of excess body weight above the ideal 
or upper normal reference for the individual was calculated as percent excess BMI loss 
(%EBMIL = ΔBMI/(initial BMI − 25) × 100), or percent excess weight loss (%EWL 
= (initial weight – postoperative weight)/(initial weight – ideal weight) x 100). For the 
calculation of %EWL in study I ideal weight was defined by the Metropolitan height 
and weight table [210] while in studies II and III, ideal weight was defined by a BMI 
of 25 kg/m2. In all three studies, the percentages of patients with weight loss below 
50% in terms of %EWL and/or %EBMIL are stated.  
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Postoperative complications and revision surgery 
In study I, we report major complications occurring early (≤ 30 days) or late (> 30 
days) in the postoperative time-span. Reoperation was reported if patients had a second 
operation due to insufficient weight loss or adverse events at any time.  
 
Obesity-related comorbidities 
In study I, we report prevalence of type 2 diabetes, hypertension, dyslipidemia, sleep 
apnea, obstructive lung disease, musculoskeletal pain, anxiety, depression and GERD. 
These conditions were considered present if patients reported relevant medical 
treatment on a regular basis. In addition, all patients were screened for type 2 diabetes, 
hypertension and dyslipidemia. Absence or remission of type 2 diabetes, hypertension 
and dyslipidemia were registered if the patient used no medication for the condition, 
and if FBS was < 7 mmol/L and HbA1c ≤ 6.4%, blood pressure was < 140/90 mmHg, 
and lipids were within normal values, respectively. For type 2 diabetes and 
hypertension, these cut-off values correspond to the definition of a partial remission by 
the ASMBS [62]. Snoring, urinary leakage, amenorrhea and infertility (in 
premenopausal women) were recorded based on self-reported symptoms, treated or 
not. Infertility was recorded if a premenopausal woman had attempted pregnancy for 
more than one year without succeeding [211].  
 
2.4.2. Patient reported outcome measures 
Quality of life 
QOL, assessed in different dimensions, is reported in all three studies. Study I includes 
a cross-sectional assessment of generic health-related QOL at five years. Study II 
reports prospectively weight-specific QOL. Study III includes three different levels of 
QOL encompassing multiple life domains. Results are compared to population norms. 
 
The Short-Form 36 
In study I and III Short-Form 36 (SF-36) was used to measure generic health-related 
QOL. The questionnaire is a valid and reliable measure of the perceived health burden 
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related to chronic diseases [212]. It has been recommended for obesity research and is 
validated for Norwegian patients with obesity [213]. The SF-36 encompasses 8 
dimensions of health, each ranging from 0 (poorest) to 100 (optimal), reflecting 1) 
physical functioning, 2) physical role functioning, 3) bodily pain, 4) general health, 5) 
vitality, 6) social functioning, 7) emotional role functioning, and 8) mental health. We 
report results from the two SF-36 summary scores based on factor analysis with oblique 
rotation; i.e. physical component summary (PCS) and mental component summary 
(MCS). The PCS and MCS cluster the eight subscales according to common physical 
and mental attributions [214]. Each of the two summary components is assessed on a 
transformed scale where higher scores represent better perceived physical and mental 
health. For comparison, we used population scores derived from a randomly selected 
Norwegian sample including all BMI categories [215]. 
 
The Impact of Weight on Quality of Life-Lite questionnaire  
In study II the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire 
was used to measure obesity-specific QOL. This is a 31-item questionnaire comprising 
1 total score and scores on 5 subdomains. These include 1) physical function, 2) self-
esteem, 3) sexual life, 4) public distress and 5) work. Scores are transformed into a 
scale from 0 to 100 where high scores indicate high obesity-specific QOL [216]. The 
IWQOL-Lite has been validated for Norwegian patients [171]. We report outcomes 
solely based on the total score. For comparison, we used data from the US general 
population, including individuals in all BMI categories [217]. 
 
The Obesity-related Problem Scale  
In study III we used the Obesity-related Problem (OP) scale to measure obesity-specific 
psychosocial functioning in different daily life situations. This questionnaire comprises 
8 items covering situations like 1) parties/social gatherings at home, 2) parties/social 
gatherings at a friend’s or relative’s place, 3) going to restaurants, 4) participating in 
organizations, attending courses, etc., 5) going on vacations, 6) trying on and buying 
clothes, 7) bathing in public areas (swimming pools, beaches), and 8) sexual 
intercourse/intimate relations with partner. Patient scores range from 0 to 3; “definitely 
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not bothered” (0), “not so bothered” (1), “mostly bothered” (2) and “definitely 
bothered” (3). A summary score is transformed to a standardized scale from 0 to 100 
where lower scores refer to higher degrees of psychosocial functioning. Scores below 
20 indicate no or mild psychosocial impairment, from 20 to < 40; mild impairment, 
from 40 to < 60; moderate impairment, from 60 to 80; severe impairment and ≥ 80; 
extreme impairment [71]. We report both total score and responses to the eight 
individual items. The OP has been psychometrically validated for Norwegian bariatric 
patients [218]. For comparison, we used population data derived from a Swedish 
sample with a BMI < 30 kg/m2 [219].  
 
Cantril’s Ladder 
In study III we applied Cantril’s ladder to measure overall QOL [220]. This widely 
used measure contains one item. Patients were asked to think of a ladder with 10 rungs 
from 0 (bottom) to 10 (top) where the top of the ladder represents the best possible life 
and the bottom represents the worst. Thereafter they were asked to “place” their own 
current life to one of the rungs – resulting in a score from 0 to 10. A score of 6 or more 
is labelled “high life satisfaction” and less than 6 “low life satisfaction”. For 




The Weight efficacy lifestyle questionnaire Short-Form  
In study II, the WEL-SF was used to measure eating self-efficacy. WEL-SF was 
originally developed for US patients undergoing bariatric [203] and later validated for 
Norwegian patients [198]. The questionnaire consists of 8 questions representing 
“confidence in ability to resist eating” related to emotional situations (3 items), 
availability of food (2 items), social pressure (1 item), positive activities (1 item) and 
physical discomfort (1 item). The Likert scale ranges from 0 (not at all confident) to 10 
(very confident), with total scores ranging from 0 to 80. Higher scores indicate higher 
eating self-efficacy. WEL-SF data from a general population was not available for 
comparison.  
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2.5. Statistical analyses 
 
Continuous variables are presented as arithmetic means ± standard deviation (SD) or 
95% confidence intervals (CI). Categorical variables are presented as counts and 
percentages (%).  
To examine longitudinal changes in binary variables, i.e. obesity-related comorbidities, 
we used the McNemar test with mid-P correction. Changes in continuous variables 
(with time as a categorical explanatory variable) were tested using mixed effects 
models with random intercept or longitudinal regression models with a heteroscedastic 
error structure (different variances at each time point) and an unstructured correlation 
matrix. These models use data from all patients, even patients with partially missing 
data. For other analyses, we used complete-case analysis, but reported the number of 
measurements on which each result was based.  
In study III, we adjusted the OP, SF-36 and Cantril’s ladder population norms for age 
and sex to reflect the same distribution as in our patient cohort. Such an adjustment 
was not done for population norms in studies I and II. The one-sample t-test was used 
to compare with the population norms [71]. 
In study II and III, associations between %EBMIL and QOL as the dependent variables, 
and other explanatory variables were investigated using multiple regression analyses. 
We performed initial tests for normal distribution of residuals, homoscedasticity, 
linearity and collinearity to ensure that underlying assumptions for the regression 
analysis were not violated. Predictors of long-term %EBMIL and disparate levels of 
QOL were assessed. In study II we chose to use ordinary least square regression based 
on available data for the predictor analysis [221]. For handling missing data in study 
III, we performed multiple imputation based on predictive mean matching and used 
imputed data in the regression models.  
To assess the clinical relevance of observed changes in PROMs, we calculated effect-
sizes as proposed by Cohen [222]. In study III, we also assessed effect-sizes of 
differences in QOL scores between the study cohort at five years and the population 
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norm. Effect sizes less than 0.2 were considered trivial, from 0.2 to 0.5 small, from 0.5 
to less than 0.8 moderate and estimates above 0.8 were considered large [222].  
Statistical analysis were performed using R 3.5.1 (R Foundation for statistical 
computing, Vienna, Austria) and Statistical Package for Social Sciences for Windows, 
version 23.0 (SPSS, Chicago, IL). Two-sided P-values ≤ 0.05 were considered 
statistically significant. No corrections for multiple tests were performed. 
Power calculations 
Initial power analyses were performed for each study cohort to estimate the risk of type 
II errors.  
Study I: Based on BMI changes from baseline to five years after surgery, N = 137, 
power = 90% and P = 0.05, we could discover a statistically significant change equal 
to 0.27 SD (paired t-test). Expected change was > 2 SD [170].  
Study II: Based on correlations between changes in eating self-efficacy, BMI and 
HRQOL, N = 114, power = 90% and P = 0.05, we could discover a statistically 
significant correlation equal to 0.29. Cross-sectional correlations with these variables 
have been reported as Pearson’s r > 0.33 [198].  
Study III: Based on changes in HRQOL from baseline to 5 years after surgery, N = 
120, power = 90% and P = 0.05 we could discover a statistically significant change 
equal to 0.30 SD (paired t-test). Expected change was > 0.76 SD [170].  
Calculations assumed a correlation between the time points of 0.5. 
 
2.6. Ethics 
Written, informed consent was obtained from the participants prior to study entry. The 
Regional Committee for Medical and Health Research Ethics – Western Norway, 
approved the studies (Reference numbers study I and III: 2009/2174, study II: 
2012/1481 and 2017/948). 
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3. Results and summary of the papers 
3.1. Study I 
Sample characteristics 
During the recruitment period a total of 168 patients accepted for VSG where included 
in the Førde registry. Complete follow-up data was available for 137 (82%) at 60 
months after surgery, with no apparent attrition bias at that point. 
 
Weight 
Weight loss was profound and significant from baseline to two and five years for the 
whole group. Mean change in BMI was 15.7 kg/m² at two years and 13.6 kg/m² at five 
years. Mean %EBMIL was 77.6% and 66.1% at two and five years, respectively. The 
weight loss varied across the cohort with a failure rate at five years of 39% (i.e., six 
patients had revision surgery for inadequate weight loss and 49 had EWL ≤50%). The 
proportion of patients with ≥ 10 kg weight regain from two to five years was 44%. 
 
Major complications and re-operations 
Major early complications occurred in 10 (6%) of the patients, including two patients 
with bleeding and two with leakage. Reoperation was performed on seven patients 
(4.2%), one due to GERD and six due to inadequate weight loss between one and three 
years after the initial operation. Four of the seven patients had a surgical conversion to 
BPDDS, one to RYGBP and two underwent a second VSG. 
 
Comorbidities 
For most obesity-related comorbidities the prevalence decreased two years after 
surgery. Exceptions were the prevalence of anxiety and depression, which remained 
unchanged, and the proportion receiving treatment for GERD, which increased. From 
two to five years, findings remained largely unchanged except for an increase in the 
proportion of patients receiving treatment for musculoskeletal pain, and a further 
increase in the number of patients taking antacids.  
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Generic health-related quality of life 
Mean PCS and MCS were 46.5 and 48.2 in the study cohort at five years, with no 
associations between %EWL and either PCS or MCS. Mean PCS and MCS at five 
years after VSG were significantly higher than preoperative scores found in a separate 
cohort of severely obese patients planned for VSG. Mean scores at five years were 
significantly lower than population norms. 
 
3.2. Study II 
Sample characteristics 
A total of 114 patients accepted for VSG agreed to participate in the study. Complete 
follow-up information was available for 84 (74%) patients at 55 months after surgery, 
with no apparent attrition bias. 
 
Weight 
Weight loss was profound with significant improvements from baseline to 16 and 55 
months for the whole group: mean change in BMI was 13.1 kg/m² from baseline to 16 
months, and 11.4 kg/m² from baseline to 55 months. The mean %EBMIL was 76% and 
67% at 16 and 55 months, respectively. Some showed less prominent weight loss with 
%EBMIL < 50% seen in 30.1% of patients at 55 months. Thirty-two percent of patients 
regained ≥ 10 kg from 16 to 55 months. 
 
Obesity-specific quality of life 
Preoperative IWQOL-Lite score increased significantly from baseline to both 16 and 
55 months, with a non-significant decline between 16 and 55 months. The effect-size 
was 1.5 at five years, indicating a large clinical relevance. At 55 months, the mean 
IWQOL-Lite score was significantly below the general population level. 
 
Eating self-efficacy 
Eating self-efficacy (WEL-SF) increased significantly from baseline to both 16 and 55 
months after VSG, with a non-significant change from 16 to 55 months. Mean change 
from baseline to 55 months was 6.8 corresponding to a small effect size of 0.4.  
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Predictors of long-term weight loss and obesity-specific quality of life 
Preoperative WEL-SF scores did not predict postoperative weight loss at 55 months. 
However, the change in WEL-SF scores from baseline to 16 months significantly 
predicted weight loss at 55 months, as did the change in eating self-efficacy from 
baseline to 55 months.   
 
Neither preoperative WEL-SF scores predicted obesity-specific QOL 55 months after 
VSG, nor did changes in WEL-SF scores from baseline to 16 months. However, change 
in WEL-SF scores from baseline to 55 months revealed a significant association to 
obesity-specific QOL at 55 months after VSG. 
 
3.3. Study III 
Sample characteristics 
During the recruitment period, a total of 150 patients accepted for VSG were identified 
in the registry, but 23 patients were later excluded from study III due to missing PRO 
data for all time-points (22 patients due to administrative errors and one patient due to 
early death not related to surgery). For the 127 patients, included PRO data was 
available in 81 (64%) patients and anthropometric data in 103 (81%) patients at 60 
months after surgery, with no apparent attrition bias. 
Weight 
For the group as a whole, mean %EBMIL was 76 and 64 after one and five years, 
respectively. A proportion of patients had less pronounced weight loss with %EBMIL 
< 50 seen in 30 out of 103 (29%) patients at five years after VSG. Thirty-eight out of 
102 (37%) patients gained ≥ 10 kg from one to five years postoperatively. 
 
Health-related QOL/QOL 
All dimensions of QOL (i.e. OP, PCS, MCS and Cantril’s ladder) improved 
significantly from baseline to one year, with a modest, but significant decline in the 
group as a whole from one to five years. The improvement in OP total score from 
baseline to five years had a large clinical relevance with an ES of 1.3. Ten out of 81 
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(8%) patients reported poorer psychosocial functioning five years after VSG than 
before.  
 
Significant improvements in mean PCS and MCS scores occurred from baseline to one 
year, followed by a subsequent modest, yet significant decline from one to five years 
after surgery. Improvements from baseline to five years showed an ES of 0.9 for PCS 
(large relevance) and 0.44 for MCS (small relevance), respectively. Twenty-one out of 
76 (17%) and 16 out of 76 (13%) patients reported poorer MCS and PCS at five years 
postoperatively than before VSG, respectively.  
 
A significant improvement from baseline to one year, followed by a modest but 
significant decline thereafter was found for Cantril’s ladder. The ES was 0.8 (large 
relevance) for the change from baseline to five years. Twenty-two out of 72 (17%) 
patients reported lower overall life satisfaction five years postoperatively than before 
VSG. 
 
Mean OP total score at five years after VSG was significantly higher than in the general 
population, indicating poorer psychosocial functioning. Furthermore, mean PCS, MCS 
and Cantril’s ladder scores at five years were significantly lower than in the reference 
population, again showing lower health-related QOL and overall QOL. These 
differences correspond to ES values of 0.7 (modest relevance) for OP, 0.4 (small) for 
PCS, 0.3 (small) for MCS and 0.8 (large) for Cantril’s ladder scores. 
 
Predictors of health-related QOL/QOL 
The three QOL domains, OP, PCS and MCS as measured at baseline significantly 
predicted their corresponding QOL outcomes at five years. A similar association was 
not seen for Cantril’s ladder. Also, baseline BMI significantly predicted the OP score 
at five years, but none of the other QOL outcome measures. Percent EBMIL at five 
years was significantly associated with OP and PCS scores, but not with MCS and 




4.1. Methodological considerations 
4.1.1. Study design and samples  
Studies I-III represent examples of prospective cohort studies. In these studies, we 
assess the effect of VSG (the exposure) on various outcomes; weight loss, 
comorbidities, complications, eating self-efficacy and QOL, within predefined groups 
of patients.  
In our studies, no control groups were used for comparison, and unknown external 
factors may have contributed to the outcomes. We therefore cannot draw firm 
conclusions about causes from our findings alone. The prospective design allows for a 
temporal comparison before and after the intervention on an individual level. 
Undoubtedly, VSG contributes to weight loss, resolution of comorbidities and 
improvement in QOL in the years following surgery. It is more difficult to assess 
whether these changes are the direct consequence of surgery alone, to what extent other 
components of the treatment, follow-up, or external factors can explain the variability 
in these outcomes. Similarly, direct comparison to outcomes seen after other surgical 
procedures is hampered. To this end, appropriately designed and conducted 
randomized controlled trials (RCTs) are required (see section 4.3.).   
In the absence of an adequate control group, multivariable analyses identify factors that 
themselves predict outcomes beyond surgery itself. In studies II and III multivariable 
regression analyses were performed to study whether available baseline characteristics, 
and their changes over time, were associated with long-term weight loss and 
improvements in QOL after VSG.  
The sample size in all three studies was relatively small, limited first and foremost by 
the number of annual VSG operations performed in the two hospitals recruiting 
patients. The number of patients could only be increased by extending the inclusion 
period, or involving other hospitals.  
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A main concern with a small sample size is the inherent risk of type II errors. Therefore, 
in all three studies a priori power calculations confirmed that the predicted lower 
bounds of differences in the main endpoints of interest would be detectable with 
adequate statistical confidence. An example of a possible type II error in study II is the 
absence of any association between baseline eating self-efficacy and weight loss or 
QOL after five years. In this study we lacked data to estimate the magnitude of 
association between the baseline WEL-SF scores and the two outcomes after five years 
for adequate power calculations. The study could only provide an initial exploration of 
this topic. 
For several of the other outcomes studied, we reported post-surgical variations below 
the threshold of statistical significance that could turn out to represent truly significant 
differences if our sample size were bigger, i.e. more patients included. This may hold 
true for instance for some of the more subtle changes in comorbidities, e.g. type 2 
diabetes, during the weight-gaining period two to five years after surgery (study I). 
Another example is the lack of association of weight loss and five year MCS, where 
the trend towards significance does not rule out a contribution detectable if larger 
cohorts were investigated (study III).  
Also, with our lower number of patients, the number of independent variables allowed 
in multivariable analyses, such as the linear regression models, is limited by standard 
statistical cautioning [223].  
 
4.1.2. Generalizability 
All three studies benefit from the inclusion of patients referred to surgery under routine 
conditions in the western health region of Norway.  
We can assume, with some reservations, that our cohorts mirror Norwegian patients 
with severe obesity that undergo bariatric surgery, i.e. the external validity seems 
adequate. We have no information about patients from the capture regions of Førde and 
Voss hospitals operated on in other public or private hospitals during the recruitment 
periods of studies I-III. About two thirds of patients in Norway are operated on in public 
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hospitals, and mostly, these patients are referred to their regional hospital. At the same 
time, we cannot control for the inherent bias that results from surgeons’ and patients’ 
choice of procedure. No uniform criteria for treatment allocation exist [224]. However, 
operations under routine conditions and study consultations as part of routine post-
operative follow-up let the results reflect the effect of current practice. By virtue of 
mirroring “real world experience”, observational studies of the kind reported herein, 
supplement results from RCTs. Due to the stringent design, strict inclusion criteria and 
selected endpoints, RCTs may not be fully representative of every day practice [225].  
For several reasons the internal validity of the results seems to be high. The number of 
VSG procedures performed during the recruitment periods can be extracted from 
hospital records and we can assess the extent to which eligible patients are included in 
the Førde registry (studies I and III) and recruited to study II at Voss hospital. At 
inclusion, this coverage is close to complete, reflecting the high willingness of patients 
and hospital staff to contribute to bariatric surgery research.  
Internal validity of longitudinal studies may be reduced by attrition, that is, loss of 
subjects during the study period. Retention rates at five years varied from 82% in study 
I, to 74% in study II and 64% in study III. For study III this was lower than expected, 
mainly due to administrative difficulties on the part of the registry. For prospective 
cohort studies, retention rates of 80% or greater are considered a standard target [226], 
but this is rarely achieved after bariatric surgery [140]. High attrition rates can 
ultimately compromise interpretation of results and violate internal validity [227]. In 
our studies, we compared baseline characteristics of patients available at five years 
with those lost during follow-up, which revealed no statistical differences in the three 
cohorts. Thus there seems to be no non-random loss of patients during follow-up and 
the internal validity does not seem to be violated by attrition.  
 
Data loss during follow-up was handled differently in the three studies. In studies I and 
II all analyses were carried out with original data and the results based on the number 
of actual data points. In study III missing data was substituted by results of multiple 
imputations, which reduces the bias introduced by non-random loss of data. Strikingly, 
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the analyses in study III yield identical results when repeated with the original data set 
– which corroborates the claim that the loss of patient data was random. 
 
4.1.3. Data quality and validity   
Compared to larger multi-institutional or registry studies, the inclusion of patients from 
only two hospitals with direct access to clinical and study-related data, allows for 
registration of a higher number of variables and a higher frequency of assessment. 
Furthermore, ambiguities in registered data may be corrected by source verification in 
medical records. Some specific aspects related to the validity of registered data are 
considered below.  
 
Comorbidities 
In most cases, registration of comorbidities was based solely on patient-reported use of 
medication. The exceptions were type 2 diabetes, hypertension and dyslipidemia for 
which biomarkers and blood-pressure measurements, represented complementary and 
objective metrics. Self-reporting of diagnoses is a common approach to collect data on 
health status [228]. However, recall bias may lead to over- or underestimating the 
presence of comorbidities. No external sources, such as prescription registries, were 
used for verification, and the duration of treatment was not recorded. Furthermore, the 
use of medication may not be a reliable indicator of disease or disease severity. For 
example, our findings for depression and anxiety in study I may be error-prone, as 
impaired mental health cannot be represented by patients’ use of medication alone. 
Study I did not include supplemental patient-reported mental health, i.e. symptoms of 
depression or psychiatric evaluations based on clinical interviews. Therefore, the 
prevalence of depression and anxiety, and its apparent relative stability must be 






Patient reported outcomes 
In all three studies PROs were captured by questionnaires that are well established in 
previous obesity research or QOL studies in other medical fields. However, some 
noteworthy points regarding the choice of questionnaires can be emphasized.  
 
Quality of life 
In study III, overall QOL was measured by Cantril’s ladder consisting of one question 
aiming to capture the patient’s satisfaction with life as a whole. Although widely tested 
and validated [229], it has rarely been used in obesity research and is not validated for 
this purpose [218]. Thus, its sensitivity for changes in the lives of bariatric patients may 
be questioned. However, the large effect-size of change detected in study III suggests 
a good capture of how patients perceive their life situation as a whole before and after 
VSG. Cantril’s ladder is similar to the visual analog scale used by Charalampakis et al, 
one of the few other studies on QOL with five years follow-up after VSG [230].  
 
Generic health-related QOL was measured by the SF-36, chosen due to its widespread 
use in obesity research and therefore useful for wider comparison of outcomes. Results 
of the two sum scores, PCS and MCS, were used as they have shown stronger stability 
in patients with obesity than the eight constituent scores on which they are based [213]. 
PCS and MCS were calculated by an oblique method allowing free correlation between 
physical and mental health as these are not independent phenomena, but inherently 
strongly linked. 
 
Obesity-specific QOL was measured with two different questionnaires, the OP scale 
and the IWQOL-Lite, both validated in Norwegian bariatric patients. While OP solely 
measures psychosocial functioning, IWQOL-Lite approaches several areas of daily life 
functioning (physical, self-esteem, sexual, public distress and work) [231]. The OP 
scale has been employed by the Førde registry to allow comparison of results with the 
SOS study [232]. Study II was planned separately and the IWQOL-Lite was chosen 




The WEL-SF is a convenient questionnaire of eating self-efficacy in bariatric patients 
due to its sensitivity for change and clinically feasible short-form properties. The 
selected situations included are obtained through exploratory factor-analyses, all 
strongly correlated with the component “confidence to resist eating” [203]. The utility 
of the questionnaire is still limited by the absence of general population data for 
comparison.   
 
In hindsight, all studies in this thesis are hampered by the lack of patient-reported 
symptoms of mental health and distress [233]. Such measures have shown to be highly 
correlated with MCS in the SF-36, still it has been suggested that symptoms of anxiety 
and depression should be measured separately and in addition to SF-36 for QOL 
assessment [234].   
 
4.2. Interpretation of outcomes in light of current data  
Knowledge on long-term outcomes after VSG has grown since the conception of the 
studies included in this thesis. The major results of studies I-III will be discussed with 
reference to new data evolved after 2016.  
 
4.2.1. Weight loss  
 “Honeymoon - with the weight just dropping off…feeling ten foot tall and bullet proof” 
[235] 
Studies I-III all include patients with severe obesity selected with uniform criteria, and 
the VSG procedure and follow-up are performed according to the same standards. 
Outcomes in terms of weight loss are remarkably similar in the three studies. For easier 
comparison and discussion, we have combined the three cohorts, using standard 
outcome measures for changes in BMI and body weight. 
In total, we have baseline anthropometric data for 409 patients. Between one and two 
years, data was available for 378 patients (92%) and at five years for 323 patients 
(79%). The mean change in BMI was 15.1 kg/m2 (± 4.9) and 12.8 kg/m2 (± 5.9) at one-
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two years and five years respectively, while corresponding figures for mean %EBMIL 
at one-two and five years was 77.0% (± 20.0) and 65.5% (± 24.5), respectively. Mean 
TWL was 32.7% (± 8.4) at one-two years after VSG, and 27.7% (± 11.0) at five years. 
A regain ≥ 10 kg from one-two to five years was observed in 121 out of 323 patients 
(37.5%). At five years, 93 out of 323 (29%) had an EBMIL < 50% whereas 120 out of 
323 (37%) obtained a BMI < 30 kg/m2. 
The combined data on five-year weight loss underscores the benefit of VSG as a stand-
alone bariatric procedure. Weight changes follow a biphasic pattern with a rapid weight 
loss during the first one-two years and a slow increase in body weight up to five years 
in a fraction of patients.  
Since the start of this PhD-work, data on long-term weight loss after VSG has 
accumulated from both observational studies [236-238] and from RCTs [239-242]. The 
efficacy of VSG in terms of weight loss for patients with severe obesity can best be 
assessed by comparison with two of the recent RCTs that report on five-year weight 
loss [240, 241]. In the SLEEVEPASS and SM-BOSS studies, patients with severe 
obesity were randomized to VSG or RYGBP and weight loss at five years was the 
primary endpoint. In the SLEEVEPASS study, including 240 patients, %EWL was 49 
at five years after VSG and 57 after RYGBP (corresponding to %EBMIL at five years 
65.5 in studies I-III). Although RYGBP was associated with greater %EWL, the 
difference was not statistically significant based on pre-specified equivalence margins. 
The SLEEVEPASS study reports %EWL by using ideal weight as the weight 
corresponding to a BMI of 25 kg/m2, that is, identical to %EBMIL. The SM-BOSS 
study randomized 217 patients and reported %EBMIL at five years of 61.1 for VSG 
and 68.3 for RYGDP, with a non-significant difference of 7.2 after correction for 
multiple testing.  
The outcomes in terms of weight loss in studies I-III compare favorably with both the 
SLEEVEPASS and SM-BOSS studies. It is reassuring that real-world routine patient 
care can achieve similar results as seen in two recent academic trials. Although both 
the SLEEVEPASS and SM-BOSS studies show modest and non-significant 
differences in weight loss in favor of RYGBP over VSG, the clinical significance of 
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this difference is not clear. Larger randomized trials with power to detect small, but 
possibly meaningful differences in efficacy are needed to address this question. To this 
end, a Swedish multicenter RCT is currently taking place to examine whether VSG is 
associated with non-inferior results in terms of weight loss compared to RYGBP. With 
the power calculations of the protocol, 2100 patients will be randomized to one out of 
two bariatric procedures - VSG or RYGBP [243].   
The two other RCTs of VSG versus RYGBP in patients with obesity are both smaller 
and not fully comparable to the cohorts in studies I-III. In the STAMPEDE trial 150 
patients with a BMI between 27 and 33kg/m2 and type 2 diabetes were randomized to 
either intensive medical treatment alone or to intensive medical treatment combined 
with either VSG or RYGBP [239]. TWL, a secondary endpoint, was 18.6% five years 
after VSG, with a small, but significant difference compared to the 23.2% TWL after 
RYGBP favoring the latter. This corresponds to TWL at five years being 27.7% in 
studies I-III. In a French single center study involving 100 patients with a BMI of 40-
60 kg/m2, %EWL at 5 years after VSG was 65.1 [242].   
There is no clear understanding of how much weight loss is needed to reverse the 
different consequences of obesity, such as comorbidities, reduced QOL or increased 
mortality. No consensus exists for what defines inadequate weight loss after bariatric 
surgery. In the combined analysis of cohorts I-III we report 29% of patients with 
EBMIL < 50% at five years, representing a group of patients with lower weight loss. 
This compares to the percentage of patients with EBMIL < 50% in VSG arm of the 
SM-BOSS trial of 31.7% [240]. In the SLEEVEPASS trial, mean EWL at 5 years after 
VSG was 49%, i.e. more than half of the patients did not reach the level of 50% EWL 
[241]. Semantically, potentially “misleading” or prejudiced terminology (success or 






4.2.2. Regain of weight 
 “Coming down to reality…everything went to custard” [235].  
 
Maintaining reduced body weight over time is a challenge to most individuals after any 
weight-loss intervention [46, 47, 245]. Weight regain, reported to start at approximately 
18-24 months [146, 150, 151], is common after all bariatric procedures [151, 246], and 
appears to be significant after VSG [141, 246, 247].  
In studies I-III we demonstrate the same biphasic weight curves after VSG, where a 
significant minority of patients steadily regain weight up until five years. Based on 
combined data from all three cohorts, 37% of the patients gained more than 10 kg 
compared to the lowest weight recorded after surgery. Interestingly, within the rigor of 
an academic trial, the SM-BOSS and SLEEVEPASS trials referred to above show 
similar weight curves characterized by a steep decline in weight until one-two years 
followed by a subsequent modest rise. From other sources with longer follow-up, likely 
inference is that this increase may continue beyond five years [248]. Bearing in mind 
the expected lifespan of most patients operated for obesity, this increase may result in 
future problems, both in terms of the weight regain itself, ensuing comorbidities and 
loss of QOL.  
The biphasic weight curve after surgery underscores the chronic nature of obesity that 
may be ameliorated, but probably not “cured” by surgery alone. Weight regain is also 
an example of where long-term results of surgery vary from one individual to another. 
In study II we found that patients regaining weight had lower eating self-efficacy 16 
months after surgery than those maintaining stable weight, and in study III we show 
that patients with lower weight loss at five years after surgery also had poorer QOL. A 
better characterization of patients at risk of regaining weight and development of 
tailored secondary prevention strategies, such as enforced follow-up, are important 





Improvements in obesity-related comorbidities reported in study I can be appraised in 
light of recently published results on long-term outcome after VSG. Among the range 
of comorbidities presented in study I, the discussion here is restricted to changes in 
type 2 diabetes, hypertension and GERD, highly relevant and commonly reported 
comorbidities in the literature on bariatric surgery. Data on dyslipidemia is presented 
in paper I and published elsewhere [145]. The stable prevalence of psychiatric 
comorbidities is presented in paper I and alluded to in different contexts of this 
discussion. However, with self-reported use of medication for anxiety and depression 
as the sole basis of this classification, the aspect of psychiatric comorbidity does not 
seem to be adequately covered in any of our studies. Due to shortage of space, other 
comorbidities are not discussed herein. 
 
Type 2 diabetes 
Preoperatively, type 2 diabetes was present in 20% of the patients included in Study I. 
Significant improvement was seen at two years after VSG, with a non-significant 
increase in the prevalence of diabetes between two and five years.  
 
In the STAMPEDE trial, control of type 2 diabetes as the primary endpoint was 
compared between three arms, intensive medical treatment on its own, or combined 
with either VSG or RYGBP [239]. The study used a level of HbA1c ≤ 6% as the 
definition of diabetes control, with or without medication. With 47 patients randomized 
to VSG and medical treatment, 11 patients (23%) achieved levels of HbA1c below this 
cut-off. The use of glucose-lowering medication, including insulin, was significantly 
reduced from baseline. In the SM-BOSS trial, 26 of the 101 patients (26%) randomized 
to VSG had type 2 diabetes, and at five years, remission (defined as HbA1c ≤ 6%, FBS 
<5.6 mmol/L and no glucose-lowering medication) was achieved in 16 of these 26 
patients (61.5%) [240]. The VSG arm of the SLEEVEPASS study included 52 out of 
121 patients (43.0%) with diabetes, and reported complete or partial remission (defined 
as HbA1c ≤ 6.4% and FBS < 7 mmol/L and no relevant medication) in 36.6% of 
available patients at five years [241]. In study I, with similar inclusion criteria as these 
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two randomized studies, 63% achieved at least a partial remission defined by the 
criteria used in the SLEEVEPASS study. The effect of VSG on resolution of type 2 
diabetes across studies is difficult to assess due to different patient cohorts, with the 
duration of type 2 diabetes prior to surgery being a possible explanation for the 
variation in outcome [241]. However, VSG is an efficient metabolic surgical procedure 
for patients with obesity in the presence of diabetes.    
 
The complex biological pathways involved in diabetes remission after obesity surgery, 
are not clearly understood. An Italian study revealed that hormonal changes (e.g. 
decreased ghrelin-, and increased GLP-1 plasma concentrations) influence glucose 
homeostasis in the early postoperative stage after VSG, but in the longer term, weight 
control determined the metabolic results [249]. The STAMPEDE trial revealed a 
significant association between initial weight loss and the rate of diabetic control at one 
year after randomization. In an analysis performed for study I, no such association was 
seen between weight loss and type 2 diabetes at any time point, but with 33 out of 168 
patients having type 2 diabetes at baseline, changing to 7 out of 152 and 13 out of 136 
at two and five years respectively, our study does not have the power to assert such 
associations.  
 
Relapse of diabetes has been reported after VSG in earlier trials [140]. In study I the 
prevalence of type 2 diabetes doubles from two to five years after VSG, but the 
difference does not reach the statistical significance threshold. This appears to be due 
to the low number of patients. The metabolic consequences of weight regain as a 
possible explanation for relapse of comorbidities, appear important also in the context 
of VSG. 
 
The STAMPEDE trial found significantly better diabetes control after medical 
treatment and surgery compared to medical therapy alone. Bariatric surgery is now 
recommended as a standard treatment option for type 2 diabetes in patients with BMI 
levels ≥ 30 kg/m2 [250]. 
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The relative efficacy of VSG in terms of glycemic control compared to other surgical 
procedures is still not fully established. The STAMPEDE trial has diabetes control as 
the primary endpoint, but with too few patients included it does not demonstrate any 
difference between VSG and RYGBP. In the SLEEVEPASS and SM-BOSS studies, 
no significant difference in outcome for patients with type 2 diabetes was detected 
during five years either. 
 
Hypertension 
Preoperatively, hypertension was present in 61% of the patients included in study I. 
This prevalence decreased significantly up to two years after VSG, and the 
improvements remained stable until the five-year point. 
 
The recent RCTs encompassing VSG show improvements in blood-pressure and 
resolution of medically treated hypertension five years after randomization [239-241]. 
The SM-BOSS study reported 64 out of 101 patients in the VSG arm with hypertension 
at baseline, which resolved to blood pressure <140/90 mm Hg and absence of 
medication in 40 patients. This corresponded to a remission rate of 62.5% [240]. In 
SLEEVEPASS, 170 of the 216 VSG patients had hypertension at baseline and 29% of 
these had discontinued anti-hypertensive medication at five years after surgery. The 
study did not report actual blood pressure measurements during follow-up [241]. In the 
STAMPEDE trial, 65% of the 134 randomized patients had hypertension at baseline 
and the authors reported improvement in both systolic and diastolic blood pressure and 
reduced use of cardiovascular medication after VSG [239]. Again due to difficulties in 
comparing the studies, the remission rate of 60 % at five years reported in study I is 
within the range of recent academic trials. 
 
The RCTs together allow no clear conclusion on whether VSG is as effective as 
RYGBP in controlling hypertension. The SLEEVEPASS study shows significantly 
better remission rates of hypertension after RYGBP than VSG, but such a difference is 
not seen in the other RCTs referred to above. In the STAMPEDE study, the reliance 
on cardiovascular medication was significantly lower in the patient groups who had 
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surgery than in the group only given medical therapy, but with no difference between 
the VSG and RYGBP groups. 
 
Gastroesophageal reflux disease 
In study I, 12 % of patients reported taking medication for GERD at baseline. The 
prevalence of patients with GERD more than doubled from baseline to five years after 
VSG and one out of seven patients needed a reoperation due to GERD.  
 
Based on early studies (section 1.3.1.), both improvement and de novo occurrence of 
GERD have been reported in patients after VSG [156, 157]. More recently, new-onset 
GERD has been related to weight regain and the development of hiatal hernia [238]. 
Furthermore, an Italian study with long-term follow-up after VSG found a high 
incidence of erosive esophagitis and Barrett’s esophagus irrespective of GERD 
symptoms, suggesting a need for systematic endoscopic surveillance after VSG [251]. 
GERD represents a major indication for reoperation after VSG, and Bohdjalian et al. 
found that 3.8% of patients had a second operation due to GERD [168, 238].  
 
The SM-BOSS and SLEEVEPASS studies allow to some extent comparison of 
resolution or development of de-novo GERD after surgery. In SLEEVEPASS, the 
baseline occurrence of GERD was not reported, but symptoms of GERD were present 
in 18 out of 121 patients during the first five years after VSG, and seven of these 
underwent reoperation [241]. No reoperation for GERD was indicated after RYGBP. 
In SM-BOSS, GERD was reported at baseline for 92 out of 205 (45%) randomized 
patients [240]. At five years after VSG, remission or worsening of GERD was reported 
for 25% and 32% of patients, compared to 60% and 6% after RYGBP, all respectively. 
New-onset GERD was reported for 32 % of patients after VSG and 11 % after RYGBP. 
Reoperations for GERD were carried out in nine out of 121 patients after VSG, and 
none after RYGBP.  
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The results concerning GERD as reported in study I are in agreement with the recent 
trials, showing worsening or de novo occurrence of GERD to be a problem of particular 
relevance to VSG.  
 
Surgical techniques to prevent deterioration or new-onset GERD, are now a part of the 
VSG procedure in many hospitals.  In a 2017 guideline, preoperative counselling 
specific to GERD-related outcomes is recommended for all patients undergoing VSG 
[252].  
 
Complications and reoperations 
Study I shows incidence of early major complications in 6% and the need for 
reoperations in 4.2% of patients. Complications included two cases of bleeding, two of 
leakage, three of deep wound infections and one of dislocated drainage. Two patients 
experienced vomiting (one due to stricture and one without pathological findings even 
after gastroscopic exploration). Reoperation was indicated in one patient due to GERD 
and in six patients due to inadequate weight loss. 
 
Despite a small sample size, the rate of early major complications in study I exceeds 
the 0.9% reported in the SM-BOSS trial, but compares favorably to the 5.8% 
complication rate after VSG in the SLEEVEPASS study. The cohort in study I overlaps 
partially with patients from Førde Central Hospital for whom early results after VSG 
were published in 2014 [145]. For completeness, it is worth underscoring that both 
studies covers the early period where VSG was first introduced as an option for patients 
with severe obesity. Together with data in study I, these two reports from Førde Central 
Hospital, where VSG was pioneered within Norway, demonstrate the procedure as 
feasible and safe in line with other bariatric procedures.   
 
The rate of late major complications, all requiring reoperations, was 10% in SM-BOSS 
and 8.3% in SLEEVEPASS. In both studies, a frequent reason for reoperations after 
VSG appears to be deterioration or de novo development of GERD. A second major 
problem necessitating reoperations appears to be inadequate weight loss, but in the 
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ASMBS recommendations this is formally not considered a complication of surgery 
[62]. Reoperations due GERD or inadequate weight loss in study I were performed 
between one and three years after the primary operation. According to a literature 
review by Felsenreich et al., the rate of conversion to other surgical operations after 
VSG increases with the length of follow-up period [238]. Adequate follow-up is 
therefore needed to estimate the rate of reoperations correctly. 
 
The recent RCTs contribute to the empirical evidence base about the relative frequency 
of post-operative complication and re-operations after VSG and RYGDP. None of the 
studies were designed specifically to measure differences in the incidence of 
complications. As mentioned before, with low patient numbers, clinically important 
differences may pass undetected. In both the SM-BOSS and SLEEVEPASS studies no 
significant differences in the rate of early complications and frequency of reoperation 
were found when comparing VSG and RYGBP, although the reasons for reoperation 
varied between the procedures. In a recent registry study summarizing real-world 
experience from more than 65000 US patients, the thirty-day rates of major adverse 
events after VSG and RYGBP were 2.6 % and 5 %, respectively, with a significant 
odds ratio of 1.57 in favor of VSG [253]. No rates of reoperations were reported, 
however. The ongoing national RCT from Sweden to compare RYGBP with VSG with 
the rate of complications as a co-primary endpoint, and will probably add important 
knowledge on the safety of the different procedures [243].  
 
 
4.2.4. Quality of life 
“The truth is in the patient” [254]. 
 
With differences in design and instruments used, all studies in scope of this thesis 
assess changes in QOL after VSG. In study I, generic health-related QOL (SF-36) was 
assessed at five years and reported to be significantly better than in an independent 
cohort of severely obese patients prior to surgery. In study II, obesity-related QOL 
(IWQOL-Lite) was improved from baseline to both 16 months and five years after 
VSG. In study III, clinically meaningful improvements were seen for three different 
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levels of QOL (OP, SF-36 and Cantril’s ladder) after VSG.  Similar to the biphasic 
weight loss pattern after VSG, serial measurements of QOL in study III show marked 
improvements at one year and modest subsequent deteriorations thereafter. A minority 
of patients reported poorer QOL five years after treatment compared to baseline.  
 
As outlined in section 1.1.4. and 1.3.4., deterioration in QOL is reported by patients 
seeking bariatric surgery, and assessment of QOL is important for evaluating the 
efficacy of surgical treatment [70, 255]. Patient self-assessments have practical utility, 
are highly relevant to patients and should therefore be included in intervention studies. 
However, patient-reports are subjective and presumably influenced by factors outside 
the control of health-care providers [255]. As endpoints in medical research, 
biomedical outcomes have traditionally been ranked higher than QOL. This trend has 
changed over the past decades, giving QOL as a patient perspective on disease an 
important complementary position. Implementing QOL assessment has contributed to 
improved understanding of symptom relief, care and rehabilitation of patients in 
multiple medical disciplines [256]. Challenges in measuring patients’ health status 
have led to development of advanced methods to evaluate the reliability and validity 
of different instruments for specific patient populations and specific conditions or 
diseases [257]. 
 
A recent systematic review of QOL research addressed concerns of conceptual and 
methodological ambiguity in QOL studies, but did not focus on obesity [258]. The 
authors noted that QOL assessment is based on subjective self-reports, i.e. PROs, but 
a large variety of questionnaires were applied to similar conditions, hampering 
comparison between studies. As for conceptual clarity, a consistent definition of QOL 
should be applied. Furthermore, QOL should be defined broadly to capture the effect 
of interventions on different life domains. In this thesis, three defined levels of QOL 
were measured; 1) overall life satisfaction (study III), 2) general physical and mental 
health-related QOL (studies I and III) and 3) obesity-specific QOL (Studies II-III) [79, 
80].   
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Prior to 2016, there were only a few reports on QOL outcomes after VSG [140]. 
Therefore, studies I-III add significant insights into five year outcomes in terms of 
different levels of QOL. All outcomes that we tracked improved significantly, but with 
varying magnitude in terms of effect size. In studies II-III the conclusion is based on a 
longitudinal and prospective comparison of patients before and after surgery. In study 
I, two separate cohorts are compared, one before and the other five years after surgery.  
Since 2016, in addition to the RCTs referenced above, QOL after VSG has been 
evaluated in one prospective long-term study from Greece [230, 239-242]. 
Charalampakis et al. found a significant improvement from baseline to two years, both 
in terms of overall and obesity-specific QOL (assessed by a visual analogue scale and 
the Moorehead-Ardelt II questionnaire) [230]. This improvement was followed by a 
significant decline from two to five years in a biphasic pattern similar to findings for 
all levels of QOL in study III. In our study II, we observed a slight deterioration in 
IWQOL-Lite from 16 to 55 months, but this difference did not reach statistical 
significance. In their smaller single-center RCT, Ignat et al. report a similar biphasic 
curve for Moorehead-Ardelt II scores after VSG, but not for the scores in the 
Gastrointestinal Quality of Life Index [242]. The SLEEVEPASS, SM-BOSS and 
STAMPEDE trials all report significant improvements in QOL (as captured by 
different tools) from baseline to five years for patients who underwent VSG, but no 
further details are reported [239-241]. In the randomized trials there is no clear 
difference between VSG and RYGBP in terms of QOL. Neither Charalampakis et al. 
nor the RCTs report details of mental health or mental health-related QOL, and no 
effect sizes that would allow estimation of the clinical significance of QOL 
improvements are provided. Collectively, the data from recent studies show that VSG 
entails a similar biphasic trajectory of QOL as do other bariatric procedures, and that a 
majority of patients benefit from surgery. 
In studies II and III, the magnitude of postoperative improvement in the different 
domains of QOL varies when looking at effect sizes from baseline to five years. The 
clinically most relevant improvements are found in obesity-specific and overall QOL. 
As suggested by others, patients seem to benefit least in terms of improved mental 
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health-related QOL, as measured by the SF-36 [176, 182]. In study III, weight loss, the 
most direct effect of surgery, predicts some of the variation in long-term obesity-
specific QOL and physical health-related QOL, but not mental health-related QOL or 
overall life satisfaction. Inclusion of mental health data in addition to QOL assessment 
may therefore be useful for better understanding of patients and improving patient-care 
before and after bariatric surgery [177, 259].  
Similarly, there is variation in individual benefits of surgery obtained for different 
levels of QOL, and factors that predict QOL outcome are not well characterized. In 
study III, between eight and 17% of patients report poorer obesity-specific- or generic 
health-related QOL, or overall QOL at five years compared to baseline. Also, weight 
loss together with other covariates evaluated in study III does not seem to predict more 
than between 13% and 36% of the variation in QOL outcome. The highest prediction 
was achieved for obesity-specific QOL, where OP scores at five years were 
significantly associated with baseline OP-scores, baseline BMI and %EBMIL at five 
years (adjusted r2 of 0.36). In study III, only sex and age were presented as covariates 
of the final models, but also marital status, level of education and medically treated 
anxiety and/or depression were explored initially without revealing significant 
associations. For reasons presented above, using medical treatment alone as a measure 
of mental disease has limitations.  
Factors other than weight and weight loss may significantly impact QOL after surgery, 
and identification of such factors merit attention in future research. Associations 
between health-related QOL after bariatric surgery, psychiatric disorders and self-
reported depressive symptoms have been suggested by others, but these aspects were 
not evaluated in depth in study III [176, 177, 185, 186].  
With this background, study II explored the possible impact of eating self-efficacy on 
obesity-specific QOL after VSG. Baseline eating self-efficacy was not associated with 
obesity-specific QOL five years after surgery, but changes in eating self-efficacy from 
baseline to 55 months were significantly and positively associated with IWQOL-Lite 
at 55 months (model 3, table 3 in Paper II). The magnitude of explained variance in 
IWQOL-Lite at five years covered by improvement in eating-self-efficacy can be 
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derived from a comparison of regression models of obesity-specific QOL in studies II 
and III presented in Table 2 below. The value for adjusted r2, the explained variance of 
model 3 in paper II, is 0.47. This number is not included in Paper II, but included in 
Table 2 below (right columns). The regression model for IWQOL-Lite scores at 55 
months, repeated without baseline eating self-efficacy or changes thereof, gives 
baseline IWQOL-Lite and %EBMIL as significant predictors with an adjusted r2 of 
0.34 (Table 2 below, mid columns). Thus 14% of the variation of long-term health-
related QOL is explained by variables representing eating self-efficacy.  An 
interpretation of these models could be that enhanced eating self-efficacy after surgery 
contributes to improved obesity-specific QOL together with, but independently of 
weight loss.  
Interestingly, the linear regression with IWQOL-Lite at five years as the dependent 
variable when omitting eating self-efficacy (Table 2 below, mid columns), is identical 
to the model for obesity-specific QOL assessed by OP scores in paper III (Table 2 
below, left columns). We also find similar significant predictors and the same level of 
explained variance (r2 of 0.36). Reassuringly, such direct comparison of the two 
independent cohorts serves to validate the models derived in studies II and III to explain 
long-term outcome in obesity-specific QOL.  
Logically, eating self-efficacy may contribute to obesity-specific QOL through 
improved eating behavior and ensuing weight loss as mediators. However, the 
independent contribution to obesity-specific QOL could have other mediators. It may 
be that consistent and enhanced cognitive control over one’s eating, such as improved 
control in difficult eating situations, contributes to a better health-related QOL more 
than what is mediated by weight loss alone.  Alternatively, the improved QOL may 
precede the improvements in eating self-efficacy. To this end, our study lack frequent 
assessments of both outcome measures (see section 4.3. on improvements in eating 
self-efficacy and weight loss). 
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Table 2. Regression models of obesity-specific QOL in studies II and III# 
Psychosocial functioning (OP) Study III Impact of Weight on Quality of life-Lite  (IWQOL-Lite) Study II 
Table 4  Table 3; model 3 
 B Coeff 95 % CI p  B Coeff 95 % CI P B Coeff 95 % CI P 
sex 2.07 -9.4, 13.5 0.723 sex 1.880 -4.927, 8.687 0.584 0.30 -5.96, 6.16 0.924 
age -0.17 -0.7, 0.3 0.480 age -0.135 -0.417, 0.146 0.340 -0.09 -0.35, 0.17 0.477 
Baseline 
BMI 
1.65 0.6, 2.7 0.003 Baseline 
BMI 
-0.177 -0.863, 0.509 0.610 -0.44 -1.07, 0.20 0.172 
%EBMIL -33.90 -52.7, -17,1 <0.001 %EBMIL 37.30* 23.60, 51.00 <0.001 25.00* 11.00, 39.00 <0.001 
Baseline 
OP 
0.32 0.1, 0.5 0.004 Baseline 
IWQOL 
-0.234 -0.411, -0.058 0.01 -0.24 -0.01, 0.43 0.008 
    Baseline 
WEL-SF 
   0.21 -0.41, 0.07 0.064 
    Change 
WEL-SF 
   0.43 0.24, 0.62 <0.001 
Adjusted 
r2 
0.358    0.336   0.469   
#The left four columns are derived from model predicting OP in Table 4 from paper IIII. The right three columns 
are derived from Model 3 in Table III in Paper II. The mid four columns present a regression model of IWQOL-
Lite with the same baseline independent variables as for OP to the left. This model allows comparison of 
predictors and explained variance, r2, between models. *For comparison, all models are presented with %EBMIL 
used as fractions between 0 and 1, not percentages between 0 and 100%. Significant associations (P < 0.05) in 
bold.  
 
Better understanding of what factors influence different levels of QOL after bariatric 
surgery could improve follow-up of patients. With inter-individual variation, these 
factors may only be evident if the specific situation of each patient is captured, for 
example by implementing relevant PROs into clinically follow-up care. Structured 
surveys by questionnaires also allow for tailored patient-centered consultations and 
health management after surgery [256]. To this end, the implementation of PROMs 
into routine care of obese patients is now piloted at Førde Central Hospital [260]. 
 
4.3. Eating self-efficacy  
“I think that emotional eating…type psychological stuff was missing and I think that’s 
what needs to kick in from twelve months onwards” [235] 
 
Bariatric surgery can induce profound and long-lasting weight loss in a large proportion 
of patients with severe obesity. The acting mechanisms appear to be mostly 
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physiological, i.e. by restrictive, absorptive or possibly endocrine changes in the 
gastrointestinal tract. Still, the results show inter-individual variability and other factors 
may contribute to this variation. As cognitive control over eating behavior seems 
important for endured weight loss after bariatric surgery, we studied eating self-
efficacy as a possible psychosocial predictor of weight loss.  
 
In study II, eating self-efficacy improved significantly from prior until 16 months after 
surgery, and remained improved at 55 months. Baseline levels of eating self-efficacy 
was not associated with weight loss. However, improvements in eating self-efficacy 
from baseline to 16 and 55 months were both associated with improved weight loss at 
55 months. 
 
To our knowledge, at the time we started this doctoral research there were no 
prospective studies of eating self-efficacy as a predictor of long-term weight loss after 
bariatric surgery. Only two cross-sectional studies showed a correlation between eating 
self-efficacy assessed one or four years after surgery and the magnitude of weight loss 
[198, 206]. However, in study II there is no association between preoperative eating 
self-efficacy scores and the extent of weight loss five years after VSG. More recent 
studies on weight loss after surgery have also failed to detect clear associations with 
either general- or eating self-efficacy [181, 261], and we have as yet no results from 
the large Swedish study [262]. Despite variations in their results, the lack of such an 
association in these studies is notably different from a number of studies where 
patients’ eating self-efficacy are assessed prior to conservative management [263-266]. 
This also contrasts to findings in other fields of health behavior, where higher self-
efficacy generally predicts improved outcomes [196, 197, 267]. 
 
Various reasons may account for the lack of association of preoperative eating self-
efficacy and weight loss after surgery.  Weight loss can only occur when the energy 
balance is negative, and patients’ net intake of calories, at least in the early 
postoperative phase up until one-two years, is therefore not closely linked to their 
preoperative level of eating self-efficacy. It is conceivable that changes in eating 
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behavior in the early phase of rapid weight loss, are enforced by surgical changes in 
the gastrointestinal tract, more than by cognitive control. This is a striking difference 
to conservative weight loss interventions, where eating behavior during and after 
treatment probably remains under cognitive control to a greater extent. An alternative 
explanation may be a severe impairment in a patient’s confidence in controlling eating 
after earlier weight loss attempts. Patients with obesity, seeking any kind of treatment, 
often look back on several and invariably failing attempts to maintain reduced weight. 
Previous “mastery experience” has been proposed as the most important source for 
high self-efficacy expectations, and in obesity, cognitive control over eating may be 
worn down by years of disappointing experiences [194]. Differences in the predictive 
power of eating self-efficacy between studies may also be explained by variations in 
baseline levels between patients opting for conservative or surgical interventions [261, 
268]. 
 
Despite the absence of associations with baseline levels, study II points to a role of 
eating self-efficacy in the long-term weight management of patients after bariatric 
surgery. Eating self-efficacy improves significantly during the first one-two years after 
surgery and changes during the first 16 months predict weight loss at both 16 and 55 
months. At five years, patients who regain weight have lower scores than those who 
maintain their weight loss. Thus, achieving a higher level of eating self-efficacy is 
associated with improved control of body weight in the long-term. It is impossible from 
an observational study alone to infer any causation. Even so, the profound weight loss 
brought about by surgery could constitute a “mastery experience” that improves the 
patient`s eating self-efficacy and subsequently alters eating behavior. The inverse 
relationship may also be true, that weight loss due to surgically enforced changes in 
eating behavior come first and subsequently enhances self-efficacy. Without frequent 
measurements of both self-efficacy, eating behavior and weight, study II allows no 
conclusion, but similar improvements in self-efficacy during conservative treatment of 
obesity have also been found [204]. In conclusion, it is possible that interventions 
during postoperative follow-up that enhance eating self-efficacy can improve long-
term outcome. 
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Study II is limited to assessing only eating self-efficacy as the psychosocial predictor 
of weight loss after surgery. However, a range of other psychosocial factors have been 
evaluated by others with no uniform results [124, 178, 181, 269]. Only sex and age are 
presented as covariates of the final models in study II, but also marital status and level 
of education were explored initially without findings of significant contributions to the 
models. Self-reported mental health was not assessed in study II. At the request of one 
reviewer during the publication process of paper II, statistical analyses of medically 
treated depression and anxiety recorded at baseline related to both weight and obesity-
specific QOL at five years postoperatively, were performed. This revealed no 
association with any of these dependent variables. However, with few patients 
reporting medically treated depression and anxiety, and with no other assessment of 
mental health, this result was omitted from the manuscript.  
 
Physical activity, a key factor in the energy balance equation, is an important aspect in 
the care of patients with obesity. In study II patients reported self-efficacy for physical 
activity at three time points. Others have identified an association of general self-
efficacy with the degree to which patients follow recommendations for physical 
activity after bariatric surgery [269]. In preparation of paper II, analyses of the 
associations between self-efficacy for physical activity, on one hand, and weight loss 
and obesity-specific QOL, on the other, were not reported on for a number of reasons: 
Firstly, there was collinearity with eating self-efficacy, prohibiting analyses in the same 
regression models. Secondly, there was no significant association with weight loss or 
obesity-specific QOL in a separate regression model, with neither baseline values nor 
changes in self-efficacy for physical activity compared from baseline to two or five 
years. Thus, to reduce the length of paper II, analyses of self-efficacy for physical 
activity were omitted from the manuscript.  
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5. Implications for practice and future perspectives 
“It is like climbing Mount Everest…and being at war for the rest of my life” [270] 
 
Results presented in studies I-III show that VSG is a safe and effective surgical 
treatment for patients with severe obesity. Relative to RYGBP, deteriorating or de novo 
occurrence of GERD is a particular concern after VSG, and therefore important 
considerations when planning for surgery in individual patients. Whether to choose 
VSG ahead of other bariatric procedures, and whether specific patient groups will 
benefit more from VSG, are still unresolved questions.  
With core concepts such as body weight, co-morbidity, QOL and self-efficacy, the 
present thesis touches upon aspects of the complex nature of obesity: the wider issues 
revolve around the multi-faceted life of individuals with a body weight higher than 
recommended medically and accepted socially. The variation in outcome and 
complexity of problems faced by at least some patients, points to potential for 
improvement in their care - before and after surgery.  
Several models have been developed to inform management of patients with obesity 
[37, 271-273].  These include socioecological models focusing on environmental and 
neuropsychological factors driving obesogenic behavior. Other models emphasize the 
chronic, relapsing and progressive nature of obesity and medical complications [272, 
274]. Based on reductionist approaches, these models run the risk of over-simplifying 
and disregarding the diversity of humans with obesity and their unique experiences, 
problems and life situations. On the contrary, the effect of bariatric surgery should 
ideally be determined by effects on health and wellbeing of the entire person, 
acknowledging health as a relative and subjective phenomenon [275].  
Direct patient involvement in health care strategies has contributed to improvements in 
clinical outcomes, patient satisfaction, and ultimately a reduction in costs and resource 
expenditure in other medical fields [276-278]. Fastenau and colleagues recently 
described an “obesity disease-illness model” with the intention to provide a patient-
centered framework to treat and support adult patients with obesity [256]. 
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Despite years of increasing body weight and numerous attempts to halt a vicious circle, 
surgery as a single intervention seems to deliver substantial weight loss with 
improvements in health status and QOL. For patients with the best outcomes, the 
combined effect of surgery and standard management including postoperative follow-
up visits at three - six months intervals, alternating at a bariatric outpatient clinic and a 
general practitioner, may be considered adequate. Identifying these patients early in the 
postoperative phase and tailoring further follow-up could be valuable, also to save 
resources. The studies in this thesis, as well as others, suggest the importance of 
evaluating the patients’ complete life situation, even in those with the best weight loss, 
since weight loss alone may not be fully representative of their general health 
perceptions. To this end, detailed patient-centered consultations are needed both before 
surgery and during follow-up for all patients. Also, educating even the best responding 
patients and their general practitioners about the requirement of follow-up seems 
important to enable further self-management [279].  
From a research perspective it would be useful to identify more comprehensively the 
factors that characterize patients with a good or worse outcome at the earliest possible 
time before or after surgery. Learning from the properties and abilities of the best 
responders could lead to improvements also for the patients with suboptimal results. 
To this end, results of paper II point to further investigation of social cognitive self-
efficacy.  
Results from our and other researchers’ studies clearly demonstrate that patients do not 
benefit equally from surgery in terms of weight loss, and that a significant subset of 
patients may experience weight regain and worsening of other problems in the 
intermediate to long-term. Despite remedying the symptoms of obesity, for these 
patients, surgery does not seem to alter sufficiently the chronic, progressive or 
relapsing nature of the disease. Lessons learned from other chronic conditions could be 
valuable and potentially incorporated into treatment of patients with clinically severe 
obesity. Thus, postoperative support may require more tailored resources, such as more 
comprehensive multidisciplinary support. Interventions to predict, prevent or correct 
weight regain are needed, possibly guided by experience in conservative intervention 
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for obesity. After lifestyle intervention and adjuvant therapy with anti-obesity drugs 
have not delivered sufficiently [111, 280], our results suggest targeting self-efficacy to 
improve cognitive control of eating behavior in the weight regain phase.   
From the patients’ perspective, a range of problems are associated with obesity, and 
measures to capture this range more fully will be valuable.  The most important 
problem for a particular patient need not be inadequate weight loss, adherence to diet 
or exercise recommendations, but rather poor sleep, low self-esteem, sexual problems, 
pain or trauma [254, 256]. To this end, broad, efficient, yet comprehensive assessment 
of patient perspectives are required. This could be supplemented by the incorporation 
of existing or future PROs into clinical consultations, enabling immediate feedback to 
both patient and clinician. This could ultimately prove valuable for the individual 
patient and more cost effective for health care funders [260].  
Today’s routine follow-up may put too little emphasis on the role of the obesogenic 
environment as a target for both preventing and treating obesity [273]. Some models 
consider traditions or expectations related to food or physical activity as social 
contagions that contribute to obesity, and suggest incorporating the personal 
environment of the patient, i.e. family and friends, into follow-up consultation. In such 
meetings, shared obesogenic behaviors may be discovered and possibly corrected. The 







“Yes, I feel scared… it just feels like the whole operation was a physical cure for a 
mental problem and of course it doesn't actually effect a cure. It gives you a handup 




Based on the purposes of studies I-III, this thesis has three main conclusions: 
1. Our findings strengthen the evidence-based knowledge on long-term results after 
VSG. Overall, VSG is a safe option for the treatment of severe obesity, providing long-
lasting weight loss and improvements in health and QOL. Both pre- and 
postoperatively, attention should be paid to symptoms of GERD. 
2. Results in terms of weight loss vary and a significant minority of patients 
experienced suboptimal long-term weight loss. There are also great variations observed 
in different levels of QOL at five years postoperatively, with a small group of patients 
reporting less benefit or even worsening of QOL. For these patients, ways to improve 
postoperative follow-up, possibly in a tailored, patient-centric manner, should be 
considered.  
3. The predictive value of early postoperative enhancement in eating self-efficacy on 
five-year postoperative weight loss, suggests to study further the relationship between 
eating self-efficacy, eating behavior and weight loss after bariatric surgery. Ultimately, 
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Abstract Background: A person’s confidence to control eating, eating self-efficacy (ESE), has been iden- 
tified as a target for long-term weight management in nonsurgical weight loss interventions, but 
has to a limited extent been studied after bariatric surgery. 
Objective: We investigated the association between ESE, weight loss, and obesity-specific quality 
of life (QOL) after sleeve gastrectomy (SG). 
Setting: A single-center longitudinal study. 
Methods: Data from adult patients were collected before SG, and at mean 16 months ( ±standard 
deviation 4 mo) and 55 ( ±4) months postoperatively. ESE was measured by the Weight Efficacy 
Lifestyle Questionnaire Short-Form. Multiple regression analyses were performed with excess 
body mass index loss (%EBMIL) and obesity-specific QOL as dependent variables. Age, sex, 
and other preoperative values were covariates in all models. 
Results: Of 114 preoperative patients, 91 (80%) and 84 (74%) were available for follow-up 
16 and 55 months after SG, respectively. Mean %EBMIL from baseline to 16 and 55 months 
was 76% (95% confidence interval: 71.9, 79.6) and 67% (95% confidence interval: 61.9, 72.2), 
respectively. Preoperative ESE scores improved significantly at both 16 and 55 months ( P = .002) 
but did not predict postoperative %EBMIL or QOL at 55 months ( β = −.08, P = .485). Greater 
change in ESE from 0 to 16 months predicted higher %EBMIL ( β = .34, P = .013) at 55 months, 
and improvements in ESE from 0 to 55 months were significantly associated with higher %EBMIL 
( β = .46, P = .001) and obesity-specific QOL ( β = .50, P < .001) 55 months after SG. 
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Conclusion: Significant improvements in ESE were seen at 16 months, and remained high at 
55 months after SG in this cohort. Patients who improved their ESE the most also experienced 
the highest weight loss and obesity-specific QOL 5 years postoperatively. Future research should 
address whether enhancement of ESE corresponds to sustained improvements in eating behavior 
after bariatric surgery. (Surg Obes Relat Dis 2019;00:1–7.) © 2018 American Society for Bariatric 
Surgery. Published by Elsevier Inc. All rights reserved. 
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Sleeve gastrectomy has globally become a preferred 
bariatric surgery treatment option, in which persistent 
( ≥5 yr) postoperative weight loss and remission of co- 
morbidities are achieved in a majority of patients [1] . How- 
ever, inadequate weight loss or weight regain is a con- 
cern after all bariatric procedures [2,3] . Obesogenic envi- 
ronments and compensatory neurobiologic mechanisms to 
hedonic eating are known barriers to weight loss mainte- 
nance [4,5] . On the other hand, specific self-regulating at- 
titudes may potentially override weight driving forces, by 
providing a sense of control, and may be important factors 
in determining the outcome after bariatric surgery [6] . 
Self-efficacy is a key concept in social cognitive theory, 
referring to an individual’s confidence in his or her ability 
to respond adequately to perceived obstacles [7] . Previous 
studies have demonstrated that self-efficacy is an impor- 
tant predictor of behavioral change in areas such as tobacco 
dependence, cardiac rehabilitation, and exercise [8,9] . Spe- 
cific to weight loss, the self-efficacy concept has shown to 
be strongly associated with self-regulating skills for weight 
management, specifically eating behavior and physical ac- 
tivity [10–12] . Within this theoretic framework, personal 
factors, behavior, and environmental influence interact re- 
ciprocally. Environmental factors (e.g., availability of food, 
or personal factors, such as former weight loss experience) 
do not impact a person’s eating behavior directly. Instead 
they influence individual confidence in reaching the desired 
weight loss. Individuals may understand that a particular 
behavior (restrictive eating) will lead to a certain outcome 
(weight loss), but such knowledge does not influence their 
(eating) behavior unless they believe in their ability to ad- 
here to it consistently [7] . A person’s self-efficacy typically 
varies from one coping area to another, and tends to change 
over time [6] . Previous mastery or failed behavioral expe- 
riences may enhance or inhibit self-efficacy, respectively, 
and can be modified by treatment [13–15] . 
Eating self-efficacy refers to a person’s confidence to 
control eating in challenging situations [16] . A few cross- 
sectional studies found significant associations between 
eating self-efficacy, and weight loss after bariatric surgery 
[10,17] . Nonsurgical weight loss interventions performed 
to increase eating self-efficacy were followed by superior 
improvements in eating behavior [18,19] . By comparing 
eating self-efficacy 4 years after either bariatric surgery or 
nonsurgical treatment for obesity, Batsis et al. [17] found 
that weight loss was associated with improvements in cur- 
rent eating self-efficacy, and that these improvements were 
more pronounced in the surgical group. However, prospec- 
tive data to examine fluctuations in eating self-efficacy be- 
fore and after bariatric surgery are needed to explore eating 
self-efficacy as a possible predictive measure for weight 
loss after surgery. 
Because restricted stomach volume and hormonal 
changes, induced by sleeve gastrectomy, dominate the reg- 
ulation of food intake and appetite the first 12 to 18 months 
postoperatively, we further examined changes in eating 
self-efficacy during the critical weight regain phase, re- 
ported to start at approximately 18 months [20,21] . 
Self-efficacy is related to positive emotions, effective 
problem solving, and life satisfaction, and may provide in- 
dividuals with a sense of control over their environment 
[6] . Hence, self-efficacious individuals tend to perceive 
high quality of life [22] . However, prospective long-term 
data on quality of life after sleeve gastrectomy are sparse 
although considered an important outcome after bariatric 
surgery [23] . In their cross-sectional study, Batsis et al. 
[17] found eating self-efficacy scores to be highly related 
to quality of life, as measured by a generic quality of life 
questionnaire [17] . Disease-specific quality of life ques- 
tionnaires contain characteristics and complaints most rel- 
evant to a disease (e.g., obesity), and tend to be more 
sensitive to change than generic measures [24] . 
Collectively, there is a need to explore the predictive 
value of eating self-efficacy on long-term outcome after 
bariatric surgery, both in terms of weight loss and obesity- 
specific quality of life. Because eating self-efficacy may 
change over time and be subject to interventions, such in- 
vestigations may assist health professionals in support of 
patients before and after surgery. 
Objective 
We investigated the predictive value of eating self- 
efficacy on weight loss and obesity-specific quality of life 
at 55 months after sleeve gastrectomy. 
Methods 
Eligible patients underwent sleeve gastrectomy during 
a 7-month period from 2012 to 2013 at Voss Hospital, 
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Western Norway. Approximately 230 bariatric operations 
are performed annually with 90% being sleeve gastrec- 
tomy. Five dedicated surgeons performed the operations 
according to a standardized procedure, using a 32-Fr tube. 
Eligibility criteria have been described previously [10,25] . 
In brief, patients were accepted if they had a body mass 
index (BMI) ≥40 kg/m ², or ≥35 kg/m ² with at least one 
obesity-associated co-morbidity, age 18 to 65 years, no al- 
cohol or drug abuse, and no active psychosis. 
After informed consent, anthropometric, demographic, 
and self-reported data were collected 3 months before 
sleeve gastrectomy, that is before initiation of preoper- 
ative dietary restriction, and during the second year at 
mean 16 months ( ± standard deviation 4 months) af- 
ter surgery. For follow-up during the fifth year, mean 
55 ( ±4) months after sleeve gastrectomy, questionnaires 
on eating self-efficacy and obesity-specific quality of life 
were sent to the patients by mail, requesting informa- 
tion about weight, medically treated co-morbidity, any late 
complications or revisional surgery. The Regional Commit- 
tee for Medical and Health Research Ethics approved the 
study. 
Outcomes 
Definitions of weight outcome 
Weight loss was presented as change in BMI 
( BMI = initial BMI −postoperative BMI) and per- 
cent excess BMI loss (%EBMIL = BMI / (initial 
BMI −25) ×100). Inadequate weight loss was reported in 
patients with revisional surgery for low weight loss, or 
%EBMIL < 50%. The number of patients gaining > 10 kg 
of weight from 16 to 55 months postoperatively is reported 
[3] . 
Patient-reported outcome measures 
Eating self-efficacy was measured by the Weight Effi- 
cacy Lifestyle Questionnaire Short-Form (WEL-SF) com- 
prising 8 questions representing the patients’ “confidence 
in ability to resist eating” related to emotional eating situ- 
ations (3 items), availability of food (2 items), social pres- 
sure (1 item), positive activities (1 item), and physical dis- 
comfort (1 item). Summed scores range between 0 and 80, 
with higher scores indicating higher eating self-efficacy. 
WEL-SF is psychometrically validated for bariatric surgery 
patients and is available in English and Norwegian [10,16] . 
Obesity-specific quality of life was measured by the 
Impact of Weight on Quality of Life-Lite (IWQOL-Lite) 
questionnaire, a 31-item questionnaire comprising a to- 
tal score and scores on 5 subdomains, including physi- 
cal function, self-esteem, sexual life, public distress, and 
work. Scores are transformed into a scale from 0 to 100, 
where high scores indicate high obesity-specific quality of 
life [24] . This measure holds strong psychometric proper- 
ties, and has been validated for Norwegian bariatric surgery 
patients [26] . 
Statistics 
Continuous variables are presented as means ± stan- 
dard deviation or 95% confidence intervals (CI). Categoric 
variables are presented as counts and percentages. As ap- 
propriate, the independent t test and χ2 test were used. 
Mixed-effect modelling was performed to study changes 
in variables over time. Effect sizes of change were calcu- 
lated and assessed for clinical relevance, according to the 
following standard criteria: trivial ( < .2), small (.2 to < .5), 
moderate (.5 to < .8), and large ( ≥.8) [27] . 
Multiple regression analyses were performed with 
%EBMIL and IWQOL-Lite (both at 55 mo) as the depen- 
dent variables, and WEL-SF as the predictor. We studied 
whether preoperative WEL-SF predicted %EBMIL, adjust- 
ing for age, sex, and preoperative BMI. Next, we studied 
whether change in WEL-SF from baseline to 16 months 
or from baseline to 55 months after surgery predicted 
%EBMIL, adjusting for age, sex, preoperative BMI, and 
preoperative WEL-SF in both models. 
In the analysis on whether preoperative WEL-SF pre- 
dicted IWQOL-Lite at 55 months, we adjusted for age, sex, 
preoperative BMI, and preoperative IWQOL-Lite. Further- 
more, we studied whether change in WEL-SF from base- 
line to either 16 or 55 months postoperatively predicted 
IWQOL-Lite, controlling for %EBMIL from baseline to 
16 or 55 months, respectively, and adjusting for age, sex, 
preoperative BMI, preoperative IWQOL-Lite, and preoper- 
ative WEL-SF in both models. 
Unstandardized and standardized beta-coefficients with 
CI are reported. As described, the clinical importance of 
regression analysis results was estimated by change in the 
dependent variables associated with a 2 standard deviation 
difference in the independent variables [28] . 
Two-sided P values ≤ .05 were considered statistically 
significant. Statistical Package for Social Sciences for Win- 
dows version 23.0 (SPSS, Chicago, IL, USA) was used. 
Results 
The study’s inclusion, attrition, and follow-up flow are 
shown in Supplementary Fig. 1. Of 127 eligible patients 
undergoing sleeve gastrectomy, 114 (67% women) with a 
mean age of 41.9 ± 11.4 years and a mean initial BMI of 
42.7 ± 4.6 kg/m ² were included. Participation rates were 
80% and 74% at 16 and 55 months, respectively. The pre- 
operative characteristics were similar in patients participat- 
ing at follow-up after 55 months and those who declined 
(Supplementary Table 1). 
Preoperative BMI decreased significantly to 16 months 
postoperatively ( P < .001). Furthermore, there was a small, 
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Table 1 
Change in weight, Weight Efficacy Lifestyle Questionnaire Short Form, and Impact of Weight on Quality of Life Lite across time. 
Measures Preoperative (n = 114) Within 16 mo (n = 91) Within 55 mo (n = 84) P value P value 
Mean CI 95%/SD Mean CI 95% Mean CI 95% 0–55 mo 16–55 mo 
BMI, kg/m ² 42.7 (41.9, 43.5) 29.6 (28.7, 30.4) 31.2 (30.3, 32.1) < .001 < .001 
Weight, kg 124.7 (121.5, 128.2) 86.1 (83.7, 88.4) 90.4 (87.7, 93.7) < .001 < .001 
%EBMIL NA 75.6 (71.9, 79.6) 66.9 (61.9, 72.2) < .001 < .001 
IWQOL-Lite total 52.1 (48.8, 55.3) 84.8 (81.1, 88.5) 83.5 (79.7, 87.3) < .001 .633 
WEL-SF 53.6 (50.5, 56.7) 59.8 (56.2, 63.0) 60.1 (56.2, 63.3) .002 .926 
CI = confidence interval; SD = standard deviation; BMI = body mass index; EBMIL = excess BMI loss; IWQOL-Lite = Impact of Weight on Quality of 
Life – Lite; WEL-SF = Weight Efficacy Lifestyle Questionnaire Short Form. 
Change over time was analyzed by mixed-effect modeling. 
but statistically significant increase in BMI from 16 to 55 
months postoperatively ( P < .001) ( Table 1 , Supplemen- 
tary Fig. 2a). This corresponds to 76% (CI: 71.9, 79.6, P < 
0.001) and 67% (CI: 61.9, 72.2, P < 0.001) %EBMIL 
from baseline to 16 and 55 months, respectively. BMI 
was 13.1 kg/m ² (CI: 12.1, 13.7, P < 0.001) from base- 
line to 16 months, and 11.4 (CI: 10.5, 12.4, P < 0.001) 
kg/m ² from baseline to 55 months. Inadequate weight loss 
(including 6 patients with revisional surgery due to low 
weight loss) was seen in 25 of 83 (30.1%) patients at 55 
months. Twenty-five of 79 patients (32%) regained weight 
of ≥10 kg from 16 to 55 months. 
Eating self-efficacy (WEL-SF) increased significantly 
from baseline to both 16 and 55 months after sleeve gas- 
trectomy ( P = .002), with a nonsignificant change from 16 
to 55 months ( P = .926) ( Table 1 , Supplementary Fig. 2c). 
Mean change from baseline to 55 months after sleeve gas- 
trectomy was 6.8 (CI: 2.7, 10.9, P = .002). The effect size 
was .4, indicating a small, clinically relevant improvement 
in eating self-efficacy from baseline to 55 months postop- 
eratively. 
Preoperative IWQOL-Lite score increased significantly 
to both 16 and 55 months ( P < .001), with a nonsignificant 
change between 16 and 55 months ( P = .633) ( Table 1 , 
Supplementary Fig. 2b). The effect size was 1.5, indicating 
a large clinically relevant improvement in obesity-specific 
quality of life from baseline to 55 months. 
We conducted 3 multiple regression analyses with 
%EBMIL at 55 months as the dependent variable ( Table 2 ). 
Preoperative score on WEL-SF did not predict weigh loss 
at 55 months postoperatively ( P = .485). However, change 
in WEL-SF scores from baseline to 16 months predicted 
weight loss at 55 months ( P = .013), as did change in eat- 
ing self-efficacy from baseline to 55 months ( P < .001). 
We conducted 3 multiple regression analyses with 
obesity-specific quality of life (IWQOL-Lite) after 55 
months as the dependent variable ( Table 3 ). Preoperative 
WEL-SF score did not predict obesity-specific quality of 
life 55 months after sleeve gastrectomy ( P = .266), nor did 
change in WEL-SF scores from baseline to 16 months 
( P = .177). However, change in WEL-SF scores from base- 
line to 55 months, revealed a highly significant correlation 
Table 2 
Multiple regression analysis with % excess BMI loss after 55 months as 
the dependent variable. 
Model 1 ∗ b (95% CI) β P value 
Age −.34 ( −.79, .10) −.17 .131 
Sex 1.47 ( −9.19, 12.15) .03 .783 
BMI baseline −1.29 ( −2.37, −.20) .26 .021 
WEL–SF baseline −.11 ( −.42, .20) −.08 .485 
Model 2 † b (95% CI) β P value 
Age −.29 ( −.74, .15) −.15 .192 
Sex 4.06 ( −6.77, 14.90) .08 .457 
BMI baseline −.93 ( −2.01, .14) −.20 .089 
WEL –SF baseline .08 ( −.29, .46) .06 .643 
Change WEL-SF 
(0–16 mo) .45 (.09, .79) .34 .013 
Model 3 ‡ b (95% CI) β P value 
Age −.25 ( −.67, .17) −.12 .247 
Sex −.50 ( −10.53, 9.52) −.01 .920 
BMI baseline −1.33 ( −2.34, .32) −.27 .010 
WEL–SF baseline .25 ( −.09, .60) .18 .149 
Change WEL-SF 
(0–55 mo) .542 (.24, .84) .46 .001 
CI = confidence interval; BMI = body mass index (kg/m ²); WEL- 
SF = Weight Efficacy Lifestyle Questionnaire Short Form. 
∗Prospective model with only baseline variables as predictors. 
† Prospective model with change in WEL-SF (0–16 mo) as main pre- 
dictor adjusted for baseline variables. 
‡ Prospective association model with Change in WEL-SF (0–55 mo) as 
the main independent variable adjusted for baseline variables. 
to obesity-specific quality of life at 55 months after sleeve 
gastrectomy ( P < .001). 
Compared with patients with successful weight loss, pa- 
tients with inadequate weight loss reported significantly 
lower eating self-efficacy (mean difference 13.0, CI: 5.8, 
20.1, P = .001) and obesity-specific quality of life (mean 
difference 15.1, CI: 8.2, 22.0, P < .001) at 55 months 
postoperatively. 
Discussion 
We prospectively determined the association between 
eating self-efficacy, weight loss, and obesity-specific qual- 
ity of life after sleeve gastrectomy. Associations were 
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Table 3 
Multiple regression analysis with Impact of Weight on Quality of Life 
Lite summary score after 55 months as the dependent variable. 
Model 1 ∗ b (95% CI) β P value 
Age −.29 ( −.60, .02) −.20 .069 
Sex 3.33 ( −4.60, 11.25) .09 .406 
BMI baseline −.67 ( −1.45, .13) −.19 .096 
IWQOL baseline −.31 ( −.53, −.10) .36 .005 
WEL–SF baseline −.13 ( −.36, −.10) −.13 .266 
Model 2 † b (95% CI) β P value 
Age −.16 ( −.46, .15) −.11 .299 
Sex 3.87 ( −3.64, 11.41) .11 .307 
BMI baseline −.26 ( −1.04, .51) −.08 .494 
%EBMIL 
(0–16 mo) .30 (.10, .49) .35 .003 
IWQOL baseline −.27 ( −.49, -0.05) −.30 .016 
WEL–SF baseline .01 ( −.27, .28) .01 .963 
Change WEL-SF 
(0–16 mo) .16 ( −.08, .40) .17 .177 
Model 3 ‡ b (95% CI) β P value 
Age −.09 ( −.35, .17) −.06 .477 
Sex .30 ( −5.96, 6.16) .01 .924 
BMI baseline −.44 ( −1.07, .20) −.12 .172 
%EBMIL 
(0–55 mo) .25 (.11, .39) .34 < .001 
WEL–SF baseline .21 ( −.01, .43) .20 .064 
IWQOL baseline −.24 ( −.41, .07) −.27 .008 
Change WEL-SF 
(0–55 mo) .43 (.24, .62) .50 < .001 
CI = confidence interval; BMI = body mass index (kg/m ²). 
IWQOL = Impact of Weight on Quality of Life – Lite; WEL-SF = Weight 
Efficacy Lifestyle Questionnaire Short Form; EBMIL = excess body mass 
index loss. 
∗Prospective model with only baseline variables as predictors. 
† Prospective model with change in WEL-SF (0–16 mo) as the main 
predictor adjusted for baseline variables and EBMIL (16 mo). 
‡ Prospective association model with change in WEL-SF (0–55 mo) as 
the main independent variable adjusted for baseline variables and EBMIL 
(55 mo). 
investigated during the short-term postoperative phase 
(0–16 mo), where most of the surgically induced weight 
loss occurs, and the long-term postoperative period where 
weight regain may follow. The purpose was to identify (1) 
whether patients’ self-efficacy toward eating is associated 
with weight loss after surgery, with a potential to override 
homeostatic weight regain mechanisms, and (2) whether 
improvements in eating self-efficacy would correspond to 
higher quality of life. 
Overall, the majority of patients in this cohort achieved 
profound and persistent weight loss associated with clin- 
ically significant improvements in eating self-efficacy 
and obesity-specific quality of life. This supports former 
research on sleeve gastrectomy as an effective treatment 
option for severe obesity [3] . Still, similar to previous 
reports, close to one third of the patients did not achieve 
the predefined limit for a successful weight loss over time 
[3,25] . There is no international recognized definition for 
what constitutes a suboptimal weight loss outcome (failure) 
after bariatric surgery, though the most commonly reported 
measure is < 50% excess weight loss [29] . Because the 
formula of percent excess weight loss is based on an ideal 
BMI = 25 kg/m 2 , %EBMIL provides the same informa- 
tion. Defining inadequate weight loss as < 50% EBMIL 
has obvious limitations on an individual level given that 
metabolic health benefits may occur even at lower levels. 
Nevertheless, as the intention was to assess associations 
between eating self-efficacy and weight change as con- 
tinuous variables, defining a lower cut-off for successful 
weight loss would not affect the main results of this study. 
We found no association between preoperative levels of 
eating self-efficacy and weight loss at 55 months after 
sleeve gastrectomy treatment, reflecting the observations 
in patients undergoing nonsurgical interventions [30] . In a 
recent review of a large number of pretreatment charac- 
teristics for weight control after nonsurgical interventions, 
including psychosocial factors, such as eating self-efficacy, 
only fewer prior weight loss attempts had a positive im- 
pact on weight loss outcome [30] . Social cognitive theory 
addresses previous “mastery experience” as the most im- 
portant source for high self-efficacy expectations [7] . Thus, 
several prior failed weight loss attempts, as is typical for 
bariatric surgery patients, may impair their confidence in 
managing their weight, wherein eating is a key issue. Con- 
sequently, their efforts toward a restrictive food intake may 
decrease. 
Instead, we found a significant increase in eating 
self-efficacy during the initial weight loss phase, and the 
improvement of eating self-efficacy remained stable 55 
months after sleeve gastrectomy. This is in accordance 
with the above observations in nonsurgically treated 
patients where treatment itself significantly improved par- 
ticipants’ eating self-efficacy [30] . In our cohort, greater 
improvement in eating self-efficacy from baseline to 16 
and 55 months predicted greater weight loss at 55 months, 
and patients with inadequate weight loss reported signif- 
icantly lower eating self-efficacy at 55 months than did 
patients with a successful weight loss. Thus, reported eat- 
ing self-efficacy closely mirrored weight loss at the same 
follow-up time point. This indicates that, due to surgically 
induced initial weight loss, patients’ confidence in their 
ability to control eating increases, and is subsequently 
maintained in correspondence with weight change. As 
such, bariatric surgery may result in a feeling of cognitive 
control through a profound mastery weight loss experience. 
The question arises whether improvements in eating 
self-efficacy in patients with sufficient weight loss simply 
mirror changes in weight, or whether these changes in eat- 
ing self-efficacy may themselves contribute to a successful 
outcome after bariatric surgery. In this regard, our study 
is limited by lack of data on the patients’ eating behavior. 
On the other hand, evidence for the predictive impact of 
domain-specific self-efficacy on disparate forms of health 
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enforcing behavior may support the latter assumption 
[6,19] . This assumtion is also in line with basic concepts 
of self-efficacy, suggesting that individuals will not make 
an effort to reduce weight unless they believe they have 
the necessary competence, eating self-efficacy, to change 
eating behavior. Because eating self-efficacy clearly is 
modifiable, our observations warrant further studies of 
eating self-efficacy as a contributing cognitive factor for 
sustained weight loss after bariatric surgery. 
Overall, obesity-specific quality of life improved signif- 
icantly in this cohort of patients treated with sleeve gas- 
trectomy. At 55 months, the mean IWQOL-Lite score was 
83.5 (CI: 79.7, 87.3), slightly below the level of 91.8 ±
12.0 reported for the U.S. general population [31] . To our 
knowledge, long-term quality of life outcome after sleeve 
gastrectomy has not been adressed in larger cohorts pre- 
viously [23,32] . The association between change in eating 
self-efficacy and obesity-specific quality of life also sug- 
gests an important contribution of patients’ perceived con- 
trol over eating to other life areas. All domains of the 
IWQOL-Lite revealed strong correlations with improve- 
ment in eating self-efficacy (data not shown), with the 
most profound association occurring in the domain “self- 
esteem.” These findings are in line with former results on 
the impact of general self-efficacy on generic quality of 
life after bariatric surgery [22] . 
Although we had a strong set of independent variables 
in this study, we cannot rule out residual and unmeasured 
confounding. For example, it could be interesting to 
investigate in future studies how patient-reported mood 
or distress relates to eating self-efficacy, weight loss and 
obesity-specific quality of life. 
Strengths of the present single center study are the 
prospective design of follow-up from before sleeve gas- 
trectomy up until the fifth year after treatment. High 
acceptance of the study among operated patients and 
prospective follow-up reduces bias introduced by attrition, 
loss to follow-up, and recall difficulties. Furthermore, 
we add novel insights by recording eating self-efficacy 
from baseline through short- and long-term postoperative 
phases believed to be influenced first by surgically induced 
restriction of food intake and later by possible homeostatic 
compensation and weight regain. 
Conclusion 
The majority of patients maintained significant weight 
loss and improvements in eating self-efficacy and obesity- 
specific quality of life at 55 months after sleeve gas- 
trectomy. Preoperative eating self-efficacy did not predict 
either weight loss or quality of life at 55-months follow-up. 
Nevertheless, greater improvement in eating self-efficacy 
between baseline and 16 months after sleeve gastrectomy 
predicted better weight loss outcome at 55 months postop- 
eratively. Improvement in eating self-efficacy at 55 months 
was significantly associated with both weight loss and 
obesity-specific quality of life. Further research should 
address whether interventions targeting enhancement of 
eating self-efficacy, during and after the initial phases 
of weight loss after bariatric surgery, can contribute to 
improvements in eating behavior. 
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AbstrACt
Objectives Sleeve gastrectomy (SG) is the most 
frequently performed bariatric surgery procedure 
worldwide, but reports on long-term quality of life (QOL) 
outcomes are scarce. We investigated 5-year trajectories 
in QOL and their associations with weight loss after SG.
Design A prospective cohort study.
setting The study was conducted in a single Norwegian 
bariatric surgery centre.
Participants Out of 150 operated patients, 127 were 
included. Mean age was 41 years, 68% were women and 
the follow-up rate at 1 year was 85% and 64% at 1 and 
5 years, respectively.
Outcome measures Data were collected preoperatively, 
and 1 and 5 years after surgery assessing three different 
levels of QOL. The main exposure was weight loss after 
SG, assessed as per cent excess body mass index (kg/m2) 
loss (%EBMIL). The Obesity-Related Problem (OP) scale 
was used to measure obesity-specific health-related QOL 
(HRQOL). Physical (PCS) and mental (MCS) composite 
summary scores of the Short Form 36 Health Survey were 
used to capture generic HRQOL and Cantril Ladder was 
used to assess overall QOL.
results All HRQOL/overall QOL measures significantly 
improved at 1 year, followed by modest decline from 1 to 
5 years after surgery. Greater %EBMIL 5 years after surgery 
was significantly associated with improvements in OP and 
PCS scores, but not with MCS and Cantril Ladder scores. 
Although significant (p<0.001) and clinically relevant 
improvements in HRQOL/overall QOL outcomes were 
observed at 5 years, scores were still below the general 
population norms.
Conclusion Most patients undergoing SG experience 
substantial weight loss accompanied by statistically 
significant and clinically relevant long-term improvements 
in HRQOL/overall QOL. However, an important minority of 
patients still report low HRQOL/overall QOL 5 years after 
SG. Further research should aim to identify other factors 
that contribute to impaired QOL after bariatric surgery, 
even in the presence of successful weight control.
IntrODuCtIOn
Impaired quality of life (QOL) is a strong 
incentive for individuals with severe obesity 
to seek help for their condition. Thus, QOL 
is considered a main measure of treatment 
efficacy after bariatric surgery.1–4 The broad 
concept of QOL encompasses overall, generic 
and disease-specific QOL domains.
Sleeve gastrectomy (SG) is now the most 
frequently performed bariatric surgery 
procedure worldwide, and keeping the intes-
tines intact is regarded as a main advantage 
compared with other surgical methods.5 
Although associated with substantial short 
(1 year) and medium-term (2–3 years) 
improvements in a range of patient-reported 
outcomes, long-term (≥5 years) reports on 
QOL after SG are scarce.6–8
To the best of our knowledge, only one 
publication reports prospective long-term 
QOL data after SG.9 In a single-centre study, 
the obesity-specific Moorehead-Ardelt II 
(MAII) questionnaire and a visual analogue 
scale to represent overall QOL were used. 
The authors reported improvements in QOL 
until 2 years, followed by subsequent declines 
from 2 to 5 years after SG. Weight loss was 
not associated with either obesity-specific or 
overall QOL. The absence of a generic ques-
tionnaire precluded comparisons with QOL 
in the general population. Cross-sectional 
reports on generic QOL using the Short 
Form 36 Health Survey (SF-36) 5 years after 
strengths and limitations of this study
 ► This prospective 5-year study expands the limited 
knowledge of long-term quality of life outcomes and 
their association with weight loss after sleeve gas-
trectomy for severe obesity.
 ► By applying obesity-specific, generic and overall 
quality of life outcome measures, the impact of 
weight loss following sleeve gastrectomy on diverse 
life domains is assessed broadly.
 ► All long-term quality of life outcomes are compared 
with general population norms.
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Figure 1 Patient flow chart from recruitment to 5-year 
follow-up.
SG are published.10–12 Comparing two similar cohorts of 
patients before and 5 years after surgery, we reported that 
mean SF-36 scores were significantly higher in the 5-year 
cohort than in the baseline cohort, although still below 
the general population norm.12 However, firm conclu-
sions on improvements in QOL cannot be drawn from 
cross-sectional studies alone and should rely on more 
than solely generic QOL measures.
Thus, the aim of this prospective study was to investigate 
long-term trajectories in QOL following SG, and to compare 
long-term QOL scores to those from the general popula-
tion. To avoid conceptual ambiguity, the broad term QOL 
was divided into three levels: (1) overall QOL representing 
satisfaction with life as a whole, (2) generic health-related 
QOL (HRQOL) representing broad domains of physical 
and mental health, and (3) obesity-specific HRQOL repre-
senting patients’ perception of QOL specifically related to 
their weight.13 Furthermore, we aimed to investigate associ-




The eligibility criteria for SG were a body mass index (BMI) 
≥40 kg/m2, or ≥35 kg/m2 with obesity-related comorbidi-
ties, age from 18 to 65 years and absence of active psychosis, 
alcohol or drug abuse. All eligible patients who under-
went SG from January 2010 to December 2013 at a single 
bariatric centre were recruited. Written informed consent 
was obtained at the preoperative outpatient visit. Preopera-
tive evaluation and follow-up were routinely performed by 
a multidisciplinary team including the surgeon, a dietitian 
and a nurse 3 months before surgery, and 3, 12, 24 and 60 
months postoperatively. Other healthcare professionals, 
such as a physiotherapist or psychologist were consulted 
as needed. Data were collected preoperatively, and during 
follow-up consultations 1 and 5 years after surgery.
Patient and public involvement
In line with requirements from the public funder of this 
research, patient involvement was ensured by discussing 
the initial study protocol with the national support group 
for people with overweight and obesity. The results will be 
disseminated to the study participants via newsletters and 
social media platforms after the study results are published.
the treatment: sleeve gastrectomy
Two surgeons performed the SG operations using a 32 
French tube as template for the resection, starting 1–2 cm 
proximal to the pylorus and ending at the cardia. The 
standardised technical procedure has been previously 
described.12 14
Demographics and clinical variables
Information on patients’ age, sex, marital/cohabitation 
status and educational level was recorded. Body weight 
was measured in light clothing without shoes to the 
nearest 0.1 kg, while height was measured in a standing 
position without shoes to the nearest 0.01 m. BMI was 
calculated as weight divided by height squared (kg/m2). 
Weight loss is presented as change in BMI (ΔBMI=ini-
tial BMI−postoperative BMI) and per cent excess BMI 
loss (%EBMIL=ΔBMI/(initial BMI−25)×100).15 We also 
report number of patients with more than 10 kg weight 
regain between 1 and 5 years16 and number of patients 
whose %EBMIL was below 50 at 5 years.17 Furthermore, 
we report number of patients whose BMI was below 
30 kg/m2 5 years after SG.18
Obesity-specific hrQOL
The Obesity-Related Problem (OP) scale, which captures 
obesity-specific psychosocial functioning in various daily life 
situations, was used to measure obesity-specific HRQOL. 
The questionnaire comprises eight items regarding (1) 
parties/social gatherings at home; (2) parties/social gather-
ings at a friend’s place; (3) going to restaurants; (4) partic-
ipating in organisations, attending courses, and so on; (5) 
going on vacations; (6) trying on and buying clothes; (7) 
bathing in public areas (swimming pools, beaches); and (8) 
sexual intercourse, intimate relations with partner. Patients’ 
statements range from 0 to 3: ‘definitely not bothered’ (0), 
‘not so bothered’ (1), ‘mostly bothered’ (2) and ‘definitely 
bothered’ (3). The summary raw total score is transformed 
to a standardised scale from 0 to 100, in which lower scores 
refer to higher degrees of psychosocial functioning. Scores 
below 20 indicate no or mild psychosocial impairment, 
from 20 to <40 mild impairment, from 40 to <60 moderate 
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Table 1 Preoperative characteristics in patients with follow-up data at 5 years compared with patients lost to follow-up
All patients n=127
Available at follow-up  
(5 years) n=81 (64%)




Age (years) 41.4±12.6 41.0±12.5 42.2±12.9 0.589
Women, n (%) 86/127 (68%) 55/81 (67.9%) 31/46 (77.4%) 0.953
BMI (kg/m², mean±SD) 44.8±6.0 44.2±2.9 46.0±6.1 0.113
Superobese (BMI ≥50 kg/m2) 22/127 (17.3%) 12/81 (14.8%) 10/46 (21.7%) 0.322
Married/cohabitants, n (%) 74/127 (58.7%) 48/81 (59.3%) 26/45 (57.8%) 0.851
Higher education, n (%)* 32/125 (25.6%) 19/81 (23.4%) 13/44 (29.5%) 0.322
Anxiety (medically treated), n (%) 13/126 (10.3%) 7/80 (8.8%) 6/46 (13.0%) 0.446
Depression (medically treated), n 
(%)
24/127 (18.9%) 15/81 (18.5%) 9/46 (19.6%) 0.855
OP total (mean±SD) 63.2±24.6 62.7±25.3 64.0±23.6 0.421
MCS (mean±SD) 42.9±10.8 43.0±10.8 42.6±11.0 0.458
PCS (mean±SD) 38.4±8.8 39.0±8.7 37.3±9.0 0.458
Cantril's Ladder (mean±SD) 4.9±1.8 5.0±1.8 4.8±1.8 0.697
*Higher education = ≥3 years at university/college. χ2 test was performed for comparing categorical variables. Independent t-test was 
performed for comparing continuous variables. Differences were considered statistically significant if p≤0.05.
BMI, body mass index;Cantril's Ladder, overall quality of life; MCS, mental composite summary score; OP total, Obesity-Related Problem 
scale total score; PCS, physical composite summary score.
extreme impairment.19 In addition to the OP total score, 
we report responses to the eight individual items. The OP 
has been translated and validated for Norwegian bariatric 
patients.20
Generic hrQOL
The SF-36 was used to measure generic HRQOL. This is 
a widely used HRQOL instrument, also recommended 
as the generic measure of choice in obesity research.21 22 
It contains 36 items with eight subscales regarding (1) 
physical functioning, (2) physical role, (3) bodily pain, 
(4) general health, (5) vitality, (6) social functioning, 
(7) emotional role functioning, and (8) mental health.23 
Herein we use the two SF-36 summary scores based 
on factor analysis with oblique rotation; that is, phys-
ical composite summary (PCS) and mental composite 
summary (MCS). The PCS and MCS cluster the eight 
subscales according to common physical and mental attri-
butions. Each of the two summary components is assessed 
on a transformed scale where higher scores represent 
better physical or mental HRQOL.23 The SF-36 is psycho-
metrically validated for use in Norwegian patients with 
severe obesity.24
Overall QOL
Cantril Ladder, containing one item, has been widely 
used in various populations and in different settings 
and is considered a valid and reliable measure of overall 
QOL.20 25 26 Respondents were asked to think of a ladder 
numbered from 0 to 10, with the best possible life being 10, 
and the worst possible life being 0. They were then asked 
to rate the perception of their own current lives on one of 
the steps between 0 and 10. A score of 6 or more is labelled 
‘high life satisfaction’ and less than 6 ‘low life satisfaction’.
General population scores on hrQOL and overall QOL
For comparison, HRQOL and overall QOL values repre-
senting the general population were obtained from 
three different data sets. Population scores on the OP 
scale were derived from a randomly selected Swedish 
sample (n=1.017) with a BMI <30.27 Population scores on 
SF-36 (n=5.396)28 and data representing Cantril Ladder 
(n=6.129)29 were derived from two randomly selected 
Norwegian samples including all BMI categories.
statistical analyses
Continuous variables are presented as means±SD or 95% 
CIs. Categorical variables are presented as counts and 
percentages (%). Available patients at 5-year follow-up 
and patients lost to follow-up were compared for baseline 
differences.
An a priori power calculation was performed based 
on previous changes observed in HRQOL from baseline 
to 5 years after biliopancreatic diversion with duodenal 
switch (BPDDS) surgery.30 With an expected n=120, 
power=90% and p=0.05 we could discover a statistically 
significant change equal to 0.30 SD (two-sided paired 
t-test). Expected change was >0.76 SD.
The BMI values, OP scale, QOL, SF-36 MCS and SF-36 
PCS scores were all modelled using longitudinal regres-
sion models with time as a (categorical) explanatory 
variable, a hetereoscedastic error structure (different 
variances at each time point) and an unstructured correla-
tion matrix. These models use data from all patients, 
even patients with partially missing data, reducing poten-
tial bias introduced by non-random loss to follow-up. 
The models were fitted using generalised least squares by 
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Table 2 Comparisons of mean QOL scores/BMI values 
at baseline, 1 year and 5 years after sleeve gastrectomy 
(n=127)*





Baseline 127 45 6 44 to 46
1 year† 125 30 5 29 to 31
5 years‡ 103 32 6 31 to 33
OP
Baseline 127 63 25 59 to 67
1 year† 110 21 21 18 to 25
5 years‡ 81 31 28 25 to 36
Effect size 1.3
SF-36 MCS
Baseline 123 43 11 41 to 45
1 year† 108 53 9 51 to 55
5 years‡ 78 48 12 45 to 50
Effect size 0.3
SF-36 PCS
Baseline 123 38 9 37 to 40
1 year† 108 52 8 51 to 54




Baseline 121 4.9 1.8 4.6 to 5.2
1 year† 109 7.4 1.6 7.1 to 7.7
5 years‡ 72 6.4 1.9 5.9 to 6.8
Effect size 0.8
*All estimates, CIs and p values are based on longitudinal models, that 
is, on the joint distribution of measurements/responses from all three 
time points (stratified by questionnaire/method).
†All p values for differences in mean scores for 1 and 5 years 
compared with baseline were <0.001.
‡All p values for differences in mean scores for 5 years compared with 
1 year were <0.001.
BMI, body mass index; MCS, mental composite summary score; OP, 
Obesity-Related Problem scale; PCS, physical composite summary 
score; QOL, quality of life; SF-36, Short Form 36 Health Survey.
items, we used paired t-tests, not adjusted for multiple 
comparisons.
To assess whether the OP total score, SF-36 (MCS and 
PCS) and Cantril Ladder at 5 years were associated with 
%EBMIL from baseline to 5 years, or could be predicted by 
baseline variables, we fitted four unadjusted and adjusted 
linear regression models. The following covariates were 
included: age, sex, baseline BMI, the corresponding base-
line HRQOL/overall QOL score of the dependent vari-
able and %EBMIL from baseline to 5 years.
For handling missing data, we used multiple imputation 
(200 imputations), based on predictive mean matching. 
This was done with the ‘aregImpute()’ function in the 
‘rms’ R package,32 with default arguments. The variables 
used in the imputation models were the ones included in 
the regression models.
Population norms for SF-36 and Cantril Ladder were 
adjusted by age and gender to reflect the same distribu-
tion as in our study sample. The method for this adjust-
ment has been described elsewhere.33 For the OP score, 
the published average non-obese population score was 
used; 58% were women and age ranged from 37 to 
61 years.19 The one-sample t-test was used to compare the 
study sample with the population norms.
Clinical relevance of changes in patient-reported 
outcomes over time was defined by calculating the mean 
difference in HRQOL/overall QOL between two time 
points divided by the pooled SD, using Cohen’s d for 
effect size (ES) ([M2–M1]/SD baseline). These ES were 
judged according to general criteria: trivial (<0.2), small 
(0.2 to <0.5), moderate (0.5 to <0.8) and large (≥0.8).34 
Cohen’s cut-offs are in accordance with findings from a 
range of study populations suggesting that a difference 
of 0.5 SD in HRQOL outcomes, either at individual or 
at group level, most likely is clinically relevant. Smaller 
ES may also be important.35 Hence, these criteria also 
guided the assessments of clinically relevant differences 
in HRQOL/overall QOL between the present cohort at 
5 years and population norms.
Statistical significance was set to p≤0.05. Analyses were 
performed using R V.3.5.136 and Statistical Package for 
Social Sciences for Windows, V.23.0 (SPSS).
The Strengthening the Reporting of Observational 
Studies in Epidemiology cohort reporting checklist was 
used according to BMJ open’s author guidelines.37
resuLts
sample characteristics
During the recruitment period, 150 patients under-
went SG. Twenty-three patients were later excluded as 
study participants; 22 because patient-reported data were 
missing at all time points due to administrative mistakes, 
and one patient died of reasons unrelated to the SG. Of 
the 127 included SG patients (mean age 41±13 years, 
68% women), complete follow-up data were available for 
85% and 64% of the patients at 1 and 5 years, respectively 
(figure 1). No statistically significant differences were seen 
in preoperative characteristics between patients available 
and lost to follow-up at 5 years postoperatively (table 1).
Change in bMI
On average, a significant decrease in BMI occurred from 
baseline to 1 year, followed by a subsequent modest, but 
statistically significant increase from 1 to 5 years after 
surgery (table 2). Mean %EBMIL was 76 (95% CI 72 to 
80) and 64 (95% CI 59 to 70) after 1 and 5 years, respec-
tively, and weight loss corresponding to %EBMIL ≥50 was 
seen in 73/103 (71%) patients at 5 years after SG. Highest 
observed %EBMIL at 5 years was 125 and the lowest was 
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Figure 2 Mean scores with 95% CIs for the eight Obesity-Related Problem (OP) scale items at baseline, 1 year and 5 years 
(n=127*). *The number of responses differed by time point and questions: 122–127 at baseline, 105–110 at 1 year and 79–81 at 
5 years.
BMI <30 kg/m2 after 5 years, and 38/103 (37%) patients 
gained ≥10 kg from 1 to 5 years postoperatively.
Changes in obesity-specific hrQOL
Significant improvement in mean OP scores occurred 
from baseline to 1 year, followed by a subsequent modest, 
but statistically significant, decline from 1 to 5 years after 
surgery (table 2). The improvement in the OP total score 
from baseline to 5 years was statistically significant with an 
ES of 1.3.
Preoperatively, 61% of the patients reported extreme or 
severe psychosocial impairment in all daily life activities 
(OP total score ≥60). One year after surgery, extreme or 
severe impairment was reported by 6% of the patients, and 
by 16% after 5 years. Four patients (5%) reported higher 
psychosocial impairment 5 years after SG compared with 
their preoperative status.
Scores on each of the eight daily life situations covered 
by the OP largely improved from baseline to 1 year 
(p<0.001) (figures 2 and 3, table 3). From 1 to 5 years, 
there were small, but significant declines (p≤0.05) for all 
situations, except for ‘bathing in public areas’ (p=0.58) 
and ‘sexual intercourse/intimate situations’ (p=0.22). 
The greatest improvement was seen for ‘trying on and 
buying clothes’, with 67% of patients reporting this activity 
to be ‘definitely bothersome’ preoperatively, compared 
with 9% at 5 years postoperatively. Patients who obtained 
a BMI <30 kg/m2 at 5 years after SG reported significantly 
higher psychosocial functioning (ie, mean OP total) than 
did patients with a BMI ≥30 kg/m2 (20 vs 35, mean differ-
ence 15, 95% CI 3.8 to 26.1, p=0.01), yet still significantly 
below the population norm (mean difference 11.5, 95% 
CI 3.7 to 19.4, p=0.005). Mean OP total score at 5 years 
was 20.6 (95% CI 14.7 to 26.6; p<0.001) points higher (ie, 
poorer psychosocial functioning) in the present cohort 
than in the population norm.19 This difference corre-
sponds to an ES of 0.7.
Changes in generic hrQOL
Significant improvements on mean PCS and MCS scores 
occurred from baseline to 1 year, followed by a subse-
quent modest, but significant decline from 1 to 5 years 
after surgery (table 2, figure 4). Nevertheless, improve-
ments from baseline to 5 years were statistically significant 
for both domains with an ES of 0.9 and 0.44 for PCS and 
MCS, respectively. Mean PCS and MCS scores at 5 years in 
the present cohort were 4.9 (95% CI 2.3 to 7.6; p<0.001) 
and 4.2 (95% CI 1.5 to 6.9; p=0.003) points lower (ie, 
poorer), respectively, than in the population norm.28 
These differences correspond to ES of 0.4 and 0.3, respec-
tively. Patients who obtained a BMI <30 kg/m2 at 5 years 
after SG reported significantly higher PCS scores than 
did patients with a BMI ≥30 kg/m2 (50.9 vs 44.1, mean 
difference 6.8, 95% CI 1.7 to 12.1, p=0.01). There was no 
significant difference in MCS scores in the two groups of 
patients.
Changes in overall QOL
Significant improvement in the Cantril Ladder mean 
score occurred from baseline to 1 year, followed by a subse-
quent modest, but significant decline from 1 to 5 years 
after surgery (table 2). The improvement from baseline 
to 5 years was still statistically significant (p<0.001) with an 
ES of 0.8. Low overall QOL (Cantril Ladder score <6) was 
reported by 67% of the patients preoperatively, compared 
with 13% and 32% of the patients at 1 and 5 years after 
SG, respectively. The mean Cantril Ladder score at 5 years 
was 1.5 (95% CI 1.1 to 2.0; p<0.001) points poorer in the 
present cohort than the population norm,29 equivalent 
to an ES of 0.8. There was no significant difference in 
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Figure 3 Individual changes in Obesity-Related Problem 
(OP) items from baseline to 5 years (n=81*). The response 
options were 0 (‘definitely not bothered’), 1 (‘not so 
bothered’), 2 (‘mostly bothered’) and 3 (‘definitely bothered’). 
The height of each bar is proportional to the number of 
patients with the corresponding response, and the width of 
the ends of each flow line is proportional to the number of 
patients with the given response pattern. *Only patients who 
answered the questionnaire at both time points are included, 
and the number of patients varied between 75 and 81 
(depending on the question).
<30 kg/m2 at 5 years after SG compared with patients with 
a BMI ≥30 kg/m2.
Associations between weight loss and hrQOL/overall QOL
In the adjusted regression models with OP, MCS, PCS and 
Cantril Ladder scores at 5 years as dependent variables, 
the baseline HRQOL/overall QOL variables predicted 
OP, MCS and PCS, but not Cantril Ladder at 5 years. In 
addition, baseline BMI predicted OP score, but none of 
the other HRQOL/overall QOL outcome measures at 
5 years. According to the adjusted model, the OP score 
increases by on average 1.7 points (95% CI 0.6 to 2.7) for 
each baseline additional BMI point. The OP total score 
decreased by on average 29.2 points (95% CI 8.7 to 49.8) 
for each additional %EBMIL between baseline and 5 years 
(table 4). Moreover, %EBMIL at 5 years was significantly 
associated with OP and PCS scores, but not with MCS and 
Cantril Ladder after 5 years. The adjusted values for R2, 
contributed by all variables together, on OP total score 
and PCS were 0.36 and 0.29, respectively.
DIsCussIOn
Principal findings and comparisons with other studies
In this prospective 5-year study of patients undergoing 
SG, we observed statistically significant and clinically 
meaningful improvements in all levels of QOL (ie, obesi-
ty-specific and generic HRQOL, and overall QOL) from 
before SG to 5 years after the procedure. In terms of 
weight loss, the average BMI dropped significantly and 
markedly during the first year with a subsequent modest 
regain in BMI occurring at 5 years. A corresponding 
pattern was seen for all QOL measures demonstrating 
significant mean improvements at 1 year, followed by a 
slight decline from 1 to 5 years postoperatively. Adjusted 
regression analyses showed that preoperative BMI signifi-
cantly predicted OP score at 5 years, and that %EBMIL 
from baseline to 5 years was significantly associated with 
both OP and PCS scores 5 years after SG. Although signifi-
cantly improved, mean total scores on both obesity-spe-
cific, generic HRQOL and overall QOL outcomes in the 
current study were below the general population norms 
5 years after SG.
The purpose of our study was to expand the limited 
knowledge on long-term changes in disease-specific and 
generic HRQOL, as well as overall QOL after SG. To our 
knowledge, only one study on long-term obesity-specific 
HRQOL and overall QOL after SG has been published, 
but the use of different questionnaires hampers direct 
comparison of HRQOL/overall QOL outcomes.9 In the 
study of Charalampakis et al, the time-dependent changes 
in weight and obesity-specific HRQOL/overall QOL were 
mainly consistent with findings in the current paper. 
Furthermore, our results on changes in HRQOL are in 
accordance with previous reports on long-term trajectories 
following BPDDS and Roux-en-Y gastric bypass (RYGBP) 
as measured by the OP scale and/or SF-36.22 38–41 Specif-
ically, Karlsson et al reported changes in OP total score 
from before to 10 years after RYGBP corresponding to 
an ES of 1.0, compared with 1.3 in the current study, that 
is, large clinically relevant improvements.38 Aasprang et al 
reported mean MCS and PCS, as measured by the SF-36, 
at 5 years after BPDDS nearly identical to the current 
study, also with small to moderate ES for improvements.40 
Long-term HRQOL scores were significantly below the 
population norm in both studies. Furthermore, Kolotkin 
et al compared HRQOL changes between RYGBP and 
non-surgery patients at 6 years using the obesity-specific 
Impact of Weight on Quality of Life-Lite (IWQOL-Lite) 
questionnaire and SF-36.39 For the RYGBP group, large 
and significant improvements in both obesity-specific and 
generic HRQOL (PCS only) were seen from baseline to 
6 years; nonetheless, PCS scores at 6 years were below US 
norms and IWQOL-Lite total score was below a non-obese 
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Table 3 Comparison of mean scores on individual items in the OP scale, at baseline, 1 year and 5 years after sleeve 
gastrectomy (n=127)
Respondents Mean SD 95% CI P value*
OP 1: Parties/social gatherings at home
  Baseline 127 1.5 1.0 1.4 to 1.7 –
  1 year 110 0.4 0.7 0.3 to 0.6 <0.001
  5 years 81 0.6 0.8 0.4 to 0.8 0.01
OP 2: Parties/social gatherings at a friend’s place
  Baseline 127 1.9 1.0 1.7 to 2.1 –
  1 year 110 0.5 0.8 0.3 to 0.6 <0.001
  5 years 81 0.8 1.0 0.6 to 1.0 0.002
OP 3: Going to restaurants
  Baseline 127 1.6 1.0 1.4 to 1.8 –
  1 year 109 0.6 0.9 0.4 to 0.8 <0.001
  5 years 81 0.8 0.9 0.6 to 1.0 0.05
OP 4: Participating in organisations, attending courses, and so on
  Baseline 125 1.6 1.0 1.5 to 1.8 –
  1 year 109 0.4 0.7 0.3 to 0.5 <0.001
  5 years 80 0.6 0.9 0.4 to 0.9 0.002
OP 5: Going on vacation
  Baseline 127 1.7 1.0 1.5 to 1.9 –
  1 year 110 0.4 0.7 0.3 to 0.5 <0.001
  5 years 81 0.7 0.9 0.5 to 0.9 <0.001
OP 6: Trying on and buying clothes
  Baseline 127 2.5 0.8 2.4 to 2.7 –
  1 year 110 0.6 0.9 0.4 to 0.7 <0.001
  5 years 81 1.0 1.0 0.8 to 1.2 <0.001
OP 7: Bathing in public areas (swimming pools, beaches)
  Baseline 127 2.5 0.9 2.3 to 2.6 –
  1 year 108 1.3 1.1 1.1 to 1.5 <0.001
  5 years 80 1.4 1.2 1.1 to 1.6 0.58
OP 8: Sexual intercourse, intimate situations
  Baseline 122 1.8 1.0 1.6 to 2.0 –
  1 year 105 0.9 1.0 0.7 to 1.1 <0.001
  5 years 79 1.0 1.1 0.8 to 1.3 0.22
*P value for change in mean score from previous time point (only based on respondents with data from both time points). The p values for 
change from baseline to 5 years are not listed, but are all <0.001.
OP, Obesity-Related Problem scale.
remarkable similarities in the pattern of long-term 
changes in HRQOL across different bariatric surgery 
procedures (gastric banding, BPDDS, RYGBP and SG), 
outcome measures and countries.22
Several researchers have suggested a dose–response 
correlation between change in weight and HRQOL.38 39 42 
In the present cohort, weight loss at 5 years after surgery 
was significantly associated with perceived obesi-
ty-specific HRQOL at 5 years. Although most patients 
reported severe to extreme psychosocial impairment 
before the operation, their reports after 1 year improved 
significantly. As weight regain occurred, the proportion 
of patients reporting severe impairment again increased. 
The clear association between %EBMIL and OP indicates 
that the patients’ perception of obesity-specific HRQOL 
is particularly sensitive to changes in BMI. Similar results 
were also reported by Karlsson et al for patients with 
10-year follow-up after RYGBP.38 In addition, Kolotkin et 
al reported that percentage excess weight loss at 6 years 
for RYGBP patients correlated significantly with changes 
in the IWQOL-Lite total score and PCS, but not MCS.39 
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Figure 4 Individual scores for the Short Form 36 Health 
Survey (SF-36) mental (MCS) and physical (PCS) composite 
summary scores (n=123*). Each point corresponds to a single 
patient. The mean score is marked with horizontal lines. The 
Norwegian general population norm is marked with a yellow 
horizontal line. *The number of patients was 123 at baseline, 
108 at 1 year and 78 at 5 years, for both PCS and MCS.
all levels of HRQOL, as weight loss at 5 years was signifi-
cantly associated only with PCS at 5 years and not MCS 
in our study. Of note, in their study on 5-year outcomes 
after SG, Charalampakis et al found no such correlations 
of weight loss and obesity-specific HRQOL, as measured 
by the MAII questionnaire.9 Furthermore, Aasprang et al 
found no significant correlations between weight loss and 
MCS and PCS using the SF-36 in their 10-year study after 
BPDDS.40
As the terms HRQOL/overall QOL encompass 
diverse life domains, one could expect a disparity in the 
influential power of weight loss on different aspects of 
life. Along these lines, we report no statistically signif-
icant associations between weight loss and broader 
QOL domains, such as overall QOL. In fact, a recent 
cross-sectional study on generic and obesity-specific 
HRQOL 4 years after bariatric surgery, controlling 
for a number of other variables that may affect QOL, 
questions the importance of weight loss as the main 
determinant of improvements in all levels of QOL after 
surgery.43 For a more accurate assessment of the rela-
tionship between surgically induced weight loss and 
QOL it appears important to differentiate between 
narrow QOL concepts, related specifically to constraints 
and concerns associated with changes of weight, and 
the broader aspects of QOL. The latter may to a larger 
degree be influenced by other weight-independent 
factors. Furthermore, despite profound weight loss in a 
majority of patients we report a noteworthy difference 
in all aspects of QOL compared with the population 
norm, suggesting that weight loss alone may be overem-
phasised in terms of improving patients’ lives. In clin-
ical practice, this calls for patient care that centres on 
other important determinants of QOL than weight loss 
alone.
strengths and limitations
Along with the prospective design and long-term follow-up, 
the present study reports broad measures of QOL covering 
overall, generic and disease-specific domains relative to 
general population scores. To our knowledge this has not 
been presented after SG before. We cannot rule out other 
factors that could possibly modify the observed relation-
ships of preoperative weight, weight loss and HRQOL/
overall QOL, such as comorbidities, stressful life events 
and eating disorders. For example, redundant skin has 
been reported as an important determinant of poorer 
psychosocial functioning and generic HRQOL after 
RYGBP.44 No systematic assessment of excessive skin and 
the degree to which this was a concern for the patients 
was done in the present cohort.
The proportion of patients lost to follow-up at 5 years 
represents a limitation. High attrition rates are common 
in longitudinal bariatric surgery research, comparable 
to the follow-up rate of 64% in the present study.8 45 
However, there were no significant baseline differences 
in registered traits comparing patients attending the 
5-year follow-up after SG and those missing. By using 
multiple imputation, any bias caused by missing data is 
reduced.
Implications and suggestions for future research
Significant and meaningful long-term improvements in 
HRQOL/overall QOL after bariatric surgery appear to be 
consistently reported. Particularly, improved psychosocial 
functioning as measured by the OP scale may considerably 
enhance patients’ performance in daily life situations. Still, 
the trend towards weight regain and concurrent decline in 
HRQOL/overall QOL after initial postoperative improve-
ments remains a concern. This underscores obesity as a 
refractory chronic condition. Though limited, some knowl-
edge exists about factors that may promote or hinder main-
tenance of weight loss.46 47 Hence, postoperative support 
may be of crucial importance to maintain successful short 
or medium-term outcomes after bariatric surgery. Several 
studies have emphasised associations between thorough 
long-term follow-up programmes and endured weight 
management.48–51 As weight control appears particularly 
important for patients’ perceived psychosocial functioning 
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components of successful weight maintenance programmes 
after surgery seems mandatory. Also, our results emphasise 
that the magnitude of weight loss does not equally influence 
all aspects of HRQOL and overall QOL. Properly distrib-
uted, this knowledge should help bariatric surgery patients 
to form realistic expectations for their well-being as a result 
of weight loss alone. Further research should aim to iden-
tify coexisting factors that may contribute to impaired QOL 
before and after bariatric surgery and address the effect of 
novel interventions to support both long-term weight loss 
maintenance and HRQOL/overall QOL after surgery.
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Paper I:  
 Figure 4 is referred to as Figure 3 in the text 
Paper II: 
 Table 1, 3rd column, “/SD” in the headline, and “SD = standard deviation” in 
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